EP2493884A1 - Co-crystal of 4-{[(6-chloropyrid-3-yl)methyl](2,2-difluoroethyl)amino}­furan-2(5h)-one with salicylic acid and use thereof as pesticide - Google Patents

Co-crystal of 4-{[(6-chloropyrid-3-yl)methyl](2,2-difluoroethyl)amino}­furan-2(5h)-one with salicylic acid and use thereof as pesticide

Info

Publication number
EP2493884A1
EP2493884A1 EP10773614A EP10773614A EP2493884A1 EP 2493884 A1 EP2493884 A1 EP 2493884A1 EP 10773614 A EP10773614 A EP 10773614A EP 10773614 A EP10773614 A EP 10773614A EP 2493884 A1 EP2493884 A1 EP 2493884A1
Authority
EP
European Patent Office
Prior art keywords
methyl
difluoroethyl
furan
amino
chloropyrid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10773614A
Other languages
German (de)
French (fr)
Inventor
Martin Weiss
Dirk Storch
Wolfgang Wirth
Britta Olenik
Hans-Christoph WEIß
Ulrich Schwiedop
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Intellectual Property GmbH
Original Assignee
Bayer Technology Services GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Technology Services GmbH filed Critical Bayer Technology Services GmbH
Priority to EP10773614A priority Critical patent/EP2493884A1/en
Publication of EP2493884A1 publication Critical patent/EP2493884A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings

Definitions

  • the invention operates new C o crystals of 4 - ⁇ [(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino ⁇ furan-2 (5H) -one with salicylic acid, as well as methods for their production and their use.
  • the compound 4 - [[(6-chloro-3-yl-yl) methyl] (2,2-difluoroethyl) amino] furan-2 (5H) -one and methods for the preparation of this compound are known. It is also known that this compound has insecticidal or acaricidal activity.
  • WO 2007/115644 A1 describes, for the first time, the preparation of this compound and its use for controlling arthropods, in particular insects. The preparation of the compound was further described in WO 2009/036899 Al. It has now been found that the compound prepared by the known method can not be applied in an economically relevant form.
  • solids can be present in amorphous and crystalline form as well as polymorphs, hydrates and solvates, which in particular can significantly influence physical properties such as solubility, bioavailability upon ingestion into an organism, hygroscopicity and melting point. These physical properties may limit or extend the utility of the substance in one way or another.
  • thermodynamically stable phase whereas in other material systems one or more transition points exist in which the stability ratio is reversed. It is not possible to predict the stability ratio and in particular the existence and location of above-mentioned transition points.
  • co-crystals Another crystalline modification of a solid is so-called co-crystals. These include the solid with so-called co-formers. Again, advantageous physical properties over the original solid can be obtained.
  • WO 2008/013823 A2 describes a process for the preparation of a carboxyl radical comprising (2R-trans) -6-chloro-5 [[4 - [(4-fluorophenyl) methyl] -2,5-dimethyl-1 - piperazinyl] carbonyl] -N, N, 1-trimethyl-alpha-oxo-1H-indole-3-acetamide or its hydrochloride or its free base and a co-former, arginine, urea, salicylic acid, 4-amino-salicylic acid and benzoic acid.
  • the disclosed co-crystals may also contain more than one co-former.
  • the stoichiometric ratio in the crystalline solid and co-former to each other may be 1: 1, 2: 1 or 1: 2. It is further described that the co-crystals found have advantageous solubility, dissolution rate, bioavailability, stability and processability.
  • the process disclosed in WO 2008/013823 A2 for the preparation of the co-crystals may be carried out by milling the crystalline solid together with the at least one co-former or co-melting of the crystalline solid with the at least one co-former, or alternatively by co-dissolving crystalline solid may be characterized with the at least one co-former and subsequent crystallization.
  • the crystalline substance and the at least one co-former may be present in a stoichiometric ratio of 1: 1 to 1: 100 to each other.
  • the aforementioned milling of the crystalline solid together with the at least one co-former may also be carried out together with a small amount of solvent.
  • thermogravimetric analysis TGA
  • powder X-ray diffractometric measurements p-XRD
  • DSC differential calorimetry
  • WO 2008/013823 A2 does not disclose a co-crystal comprising 4 - ⁇ [(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino ⁇ furan-2 (5H) -one.
  • WO 2008/013823 A2 discloses that it is generally possible that co-crystals of a crystalline solid may be distinguished by an improvement in the abovementioned physical properties, this is in connection with the processes described in WO 2008/013823 A2 disclosed co-crystals are not disclosed. It also seems doubtful whether the disclosed co-crystals actually exist. Only hints are disclosed that the co-crystals could exist.
  • a final proof by the cultivation of a single crystal and its measurement is not revealed. The revealed Powder X-ray diffractometric measurements can also convey misinformation by diffraction and refraction at the particle surfaces.
  • US 2007/0212683 A1 discloses a co-crystal of VX-950, a hepatitis C virus inhibitor with, inter alia, oxalic acid.
  • the resulting co-crystals can have advantageous physical properties. Although a stability measurement of a suspension of the co-crystal is disclosed, a comparative disclosure between the pure crystalline solid and the co-crystals can not be found. In addition, the existence of the disclosed co-crystals may also be doubtful in the disclosure of US 2007/0212683 Al, since in this case too only powder X-ray diffractometric measurements were carried out with the error sources resulting from them.
  • WO 2008/096005 AI describes thiophanate-methyl as a co-former for agrochemically active substances which must comprise at least one functional group which acts as a hydrogen acceptor of a hydrogen bond.
  • co-crystal means a solid substance at room temperature (23 ° C) and ambient pressure (1013 hPa) containing in its crystal lattice at least two hydrogen bonds with interacting pure substances, wherein all pure substances present in the crystal lattice are also solids at room temperature (23 ° C) and ambient pressure (1013 hPa).
  • co-former denotes a pure substance which is not 4 - ⁇ [(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino ⁇ furan-2 (5H) -one and which together with 4 - ⁇ [(6-chloro-3-yl-yl) methyl] (2,2-difluoroethyl) amino ⁇ furan-2 (5H) -one are in at least a stoichiometric ratio Adukt forms, which has only one melting point.
  • the co-crystal according to the invention usually has a melting point which is higher than that of the pure substance 4 - ⁇ [(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino ⁇ furan-2 (5H) -one.
  • melting point is understood as the temperature at which the substance has the highest heat output when measuring the melting point in a differential calorimetry (DSC). Melting of the substance begins earlier than at the temperature at which the aforementioned highest heat output is to be measured and usually ends at higher temperatures, which is why the below-mentioned melting points according to other definitions of the melting point quite well at lower or higher temperatures can.
  • DSC differential calorimetry
  • the increased melting point of the co-crystal according to the invention is particularly advantageous because the Co crystal, in contrast to the pure substance 4 - ⁇ [(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino ⁇ furan-2 (5H ) -one can be treated at higher temperatures without melting.
  • Such treatment at higher temperatures may be drying in the course of producing the co-crystal, or else storage at elevated temperatures.
  • the co-crystal according to the invention exhibits improved storage stability since, when stored at elevated temperatures, it does not tend to melt on its surface and thus agglomerate or adhere to the wall of the transport container in which it is transported.
  • the co-crystal according to the invention usually has a higher solubility in water than the pure substance 4 ⁇ [(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino ⁇ furan-2 (5H) -one.
  • the Co crystal consists essentially of 4 - ⁇ [(6-chloro-3-yl-yl) methyl] (2,2-difluoroethyl) amino ⁇ furan-2 (5H ) -one and salicylic acid as co-formers.
  • the melting point of the co-crystal according to the invention is usually in the range of 70 ° C to 90 ° C, co-crystals according to the invention having a melting point of about 82 ° C are preferred.
  • the aforementioned melting point can be determined in a well-known manner by differential calorimetry (DSC).
  • the stoichiometric ratio of 4 - ⁇ [(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino ⁇ furan-2 (5H) -one to salicylic acid in the first preferred embodiment is 1: 1.
  • the co-crystal according to the first preferred embodiment of the present invention is further characterized as having a monoclinic morphology.
  • the co-crystal usually has the space group P2 (I) / n according to Cambridge structure database (FL, Allen, Acta Cryst.B58, (2002) 380-388).
  • a further subject of the present invention is a first process for preparing a cocrystal comprising 4 - ⁇ [(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino ⁇ furan-2 (5H) -one, characterized in that it comprises at least the steps
  • step a) of the process according to the invention can be carried out by either 4 - ⁇ [(6-chloro-3-yl-3-yl) methyl] (2,2-difluoroethyl) amino ⁇ furan-2 (5H) -one and salicylic acid is added, or vice versa.
  • the 4 - ⁇ [(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino ⁇ furan-2 (5H) -one is initially introduced and salicylic acid is added by weighing.
  • the mixture A obtained in step a) of the process according to the invention may comprise 4 - ⁇ [(6-chloro-3-yl) methyl] (2,2-difluoroethyl) amino ⁇ furan-2 (5H) -one and salicylic acid contain any stoichiometric ratios.
  • the mixture A preferably contains 4 - ⁇ [(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino ⁇ furan-2 (5H) -one in a stoichiometric ratio of 1: 1 to salicylic acid.
  • step b) the mixing according to step b) is carried out.
  • the solvent used according to step b) of the process according to the invention may be any suitable solvent which is capable of at least one of the substances salicylic acid and / or 4 - ⁇ [(6-chloropyrid-3-yl) methyl] (2,2-) difluoroethyl) amino ⁇ furan-2 (5H) -one in a concentration of at least 0.01 g / 1.
  • suitable solvents are in particular acetone, ethyl acetate, ethanol and 2-propanol and mixtures thereof.
  • step b) of the process according to the invention the solvent is added in an amount such that in the resulting mixture A 'the solubility concentration (solubility) of 4 - ⁇ [(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl ) amino ⁇ furan-2 (5H) -one and / or salicylic acid is exceeded.
  • the solubility concentration of 4 - ⁇ [(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino ⁇ furan-2 (5H) -one and salicylic acid is exceeded.
  • the presence of the solvent can not prevent the formation of molecular adducts in the sense of hydrogen bonding between 4- ⁇ [(6- Chlo ⁇ yrid-3-yl) methyl] (2,2-difluoroethyl) amino ⁇ furan-2 (5H) -one and the respective co-former significantly.
  • Milling of mixture A or mixture A ' may be carried out in any apparatus known to those skilled in the art for grinding solids.
  • Non-exhaustive examples of devices in which such grinding can be carried out are, for example, mortar mills, vibrating mills or ball mills.
  • step c) of the process according to the invention is carried out in vibratory mills or ball mills.
  • the energy introduced into the material to be ground must be sized so as not to result in the unwanted formation of amorphous phases of the solids, but at the same time intensive contacting of the solids in the milling apparatus takes place.
  • suitable parameters with which he can set this energy include, for example, the duration and intensity (for example, the impact pressure of a mortar mill or size and material, as well as the amplitude and frequency in a vibratory mill or rotational speed in a ball mill) of grinding.
  • Such procedures are particularly advantageous because, by limiting the energy input, it is possible to ensure that a minimum of intense exposure of 4 - ⁇ [(6-chloropyrid-3-yl) methyl] (2 , 2-difluoroethyl) amino ⁇ furan-2 (5H) -one is carried out with the co-former salicylic acid, while at the same time avoiding excessive stress on the substances due to the limitation to the top.
  • Such excessive stress on the materials being ground may cause them to be converted to an amorphous state, possibly preventing the formation of a co-crystal or destroying a formed co-crystal.
  • the entire process is usually carried out at room temperature (23 °) and ambient pressure (1013 hPa). However, it may be appropriate to carry out the process and in particular the step c) at lower temperatures in order to tolerate some heating of the materials to be ground can, without the energy entry results in the aforementioned transfer to the amorphous state.
  • a further subject of the present invention is a second process for preparing a cocrystal comprising 4 - ⁇ [(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino ⁇ furan-2 (5H) -one, characterized in that it comprises at least the steps a) providing a saturated solution (A) of 4 - ⁇ [(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino ⁇ furan-2 (5H) -one and / or a saturated solution (B ) of salicylic acid, and
  • the solution (A) can be prepared with a first solvent and the solution (B) can be prepared with a second solvent.
  • the first and second solvents may be independently selected from a list consisting of acetone, ethyl acetate, ethanol, 2-propanol and water or mixtures thereof.
  • the first and second solvents are the same.
  • step a) of the second process according to the invention only one solution (A) or one solution (B) may also be present. If only one solution (A) or one solution (B) is provided according to the step a) of the method, then in step b) either salicylic acid as a solid is added to the solution (A) or to the solution (B) 4- ⁇ Added [(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino ⁇ furan-2 (5H) -one as a solid.
  • the second process according to the invention is preferably carried out such that in step a) the solutions (A) and (B) are provided and these solutions are mixed with one another without the addition of further solid.
  • Another object of the present invention is the use of co-crystals of 4 - ⁇ [(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino ⁇ furan-2 (5H) -one invention with salicylic acid as Co-formers for combating animal pests, in particular insects, arachnids and / or nematodes, which are found in agriculture, in forests, in the protection of stored products and materials and in the hygiene sector.
  • plants and plant parts can be treated within the scope of the use of the co-crystals according to the invention.
  • plants are understood as meaning all plants and plant populations, such as desired and undesired wild plants or crop plants (including naturally occurring crop plants).
  • Crop plants can be plants that can be obtained by conventional breeding and optimization methods or by biotechnological and genetic engineering methods or combinations of these methods, including the transgenic plants and including the plant protectable or non-protectable plant varieties.
  • Plant parts are to be understood as meaning all aboveground and underground parts and organs of the plants, such as shoot, leaf, flower and root, examples of which include leaves, needles, stems, stems, flowers, fruiting bodies, fruits and seeds, as well as roots, tubers and rhizomes.
  • the plant parts also include crops and vegetative and generative propagation material, such as cuttings, tubers, rhizomes, offshoots and seeds.
  • the treatment according to the invention of the plants and plant parts with the co-crystals according to the invention is carried out directly or by acting on their environment, habitat or storage space according to the usual treatment methods, e.g. by dipping, spraying, evaporating, atomizing, spreading, brushing, injecting and in propagating material, in particular in seeds, further by single or multilayer coating.
  • plants which can be treated in the context of the above-mentioned use of the co-crystals according to the invention the following may be mentioned: cotton, flax, grapevine, fruits, vegetables, such as Rosaceae sp. (for example, pome fruits such as apple and pear, but also drupes such as apricots, cherries, almonds and peaches and soft fruits such as strawberries), Ribesioidae sp., Juglandaceae sp., Betulaceae sp., Anacardiaceae sp., Fagaceae sp., Moraceae sp., Oleaceae sp., Actinidaceae sp., Lauraceae sp., Musaceae sp.
  • Rosaceae sp. for example, pome fruits such as apple and pear, but also drupes such as apricots, cherries, almonds and peaches and soft fruits such as strawberries
  • Rubiaceae sp. for example, coffee
  • Theaceae sp. Sterculiceae sp.
  • Rutaceae sp. for example, lemons, organs and grapefruit
  • Solanaceae sp. for example tomatoes
  • Liliaceae sp. for example, Asteraceae sp.
  • Umbelliferae sp. for example, Cruciferae sp., Chenopodiaceae sp., Cucurbita ceae sp. (for example cucumber), Alliaceae sp. leek, onion), Papilionaceae sp.
  • Main crops such as Gramineae sp. (for example corn, turf, cereals such as wheat, rye, rice, barley, oats, millet and triticale), Asteraceae sp. (for example sunflower), Brassicaceae sp. (for example, white cabbage, red cabbage, broccoli, cauliflower, Brussels sprouts, pak choi, kohlrabi, radishes and rapeseed, mustard, horseradish and cress), Fabacae sp. (for example, beans, peanuts), Papilionaceae sp. (for example, soybeans), Solanaceae sp. (for example potatoes), Chenopodiaceae sp.
  • Gramineae sp. for example corn, turf, cereals such as wheat, rye, rice, barley, oats, millet and triticale
  • Asteraceae sp. for example sunflower
  • Brassicaceae sp. for example, white cabbage, red cabbage
  • the present invention further provides compositions for controlling animal pests, in particular insects, arachnids and / or nematodes, which are found in agriculture, in forestry, in the protection of stored products and in the hygiene sector, and which comprise the co-product of the invention. Include crystals.
  • the co-crystals of the present invention are generally useful as starting materials for the preparation of any of the compounds 4 - ⁇ [(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino ⁇ furan-2 (5H) formulated agent for control of chicks, even when the compound is 4 - ⁇ [(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino ⁇ furan-2 (5H) -one according to the Formulation is no longer present as a co-crystal, but rather in dissolved form.
  • co-crystals according to the invention are suitable for the production of compositions for the treatment of seed.
  • the present invention therefore also relates, in particular, to a method for the protection of seeds, in particular transgenic seed, and germinating plants from the infestation of pests, in which the seed is treated with one of the agents according to the invention.
  • the invention also relates to the use of the agents according to the invention for the treatment of seeds for the protection of the seed and the resulting plant from pests. Furthermore, the invention relates to seed which has been treated with an agent according to the invention for protection against pests.
  • transgenic seed contains at least one heterologous gene which controls the expression of a polypeptide having in particular insecticidal properties.
  • the heterologous genes in transgenic seed can come from microorganisms such as Bacillus, Rhizobium, Pseudomonas, Serratia, Trichoderma, Clavibacter, Glomus or Gliocladium.
  • the present invention is particularly useful for the treatment of transgenic seed containing at least one heterologous gene derived from Bacillus sp. and its gene product Efficacy against European corn borer and / or corn rootworm shows. Most preferably, this is a heterologous gene derived from Bacillus thuringiensis.
  • One of the advantages of the present invention is that, owing to the particular systemic property of the 4 - ⁇ [(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino ⁇ fluorine contained in the C o crystals according to the invention, 2 (5H) -one of the treatment of the seed with the agents according to the invention not only protects the seed itself, but also the resulting plant after emergence, from pests.
  • compositions containing the co-crystals of the invention Preference is given to compositions which contain less than 20% by weight of the co-crystals according to the invention, more preferably less than 15% by weight, very particularly preferably less than 10% by weight, particularly preferably less than 5% by weight, most preferably containing less than 4, 3, 2 or 1% by weight of the co-crystals of the invention in the composition. According to the invention, compositions also comprise the aforementioned agents.
  • the co-crystals according to the invention can be converted into the customary formulations in a known manner, such as suspension concentrates, oil-based suspension concentrates, colloidal concentrates, dispersible concentrates, emulsifiable concentrates (emulsion concentrates), emulsion mordants, suspension mordants, granules, microgranules, suspoemulsions, water-soluble granules, water-soluble concentrates and water-dispersible granules, using suitable auxiliaries and carriers or solvents.
  • suspension concentrates oil-based suspension concentrates, colloidal concentrates, dispersible concentrates, emulsifiable concentrates (emulsion concentrates), emulsion mordants, suspension mordants, granules, microgranules, suspoemulsions, water-soluble granules, water-soluble concentrates and water-dispersible granules, using suitable auxiliaries and carriers or solvents.
  • the active compound 4 - ⁇ [(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino ⁇ furan-2 (5H) -one in a concentration of about 0.5 to 90 wt. % of the composition containing the co-crystals according to the invention, ie in amounts sufficient to achieve the necessary dosage level.
  • the formulations are prepared by stretching the co-crystals of the invention with water, solvents and / or carriers, optionally using emulsifying and / or disperse powers, and / or the other adjuvants, e.g. B. Penetration aids.
  • suspension concentrates including those used for seed treatment
  • further adjuvants are generally added in addition to the active ingredient and an extender (water, solvent or oil).
  • an extender water, solvent or oil
  • a wetting agent is used to stabilize the suspension in the liquid phase
  • dispersing agents are used for emulsifying the non-aqueous phase are used in solvent or oil-containing suspension concentrates emulsifiers.
  • anti-freeze agents, biocides, thickeners, dyes, spreading agents and / or absorption promoters are incorporated.
  • the co-crystals according to the invention can furthermore be converted into other customary formulations, such as solutions, emulsions, wettable powders, water- and oil-based suspensions, powders, dusts, pastes, soluble powders, soluble granules, scattering granules, suspension-emulsion concentrates, co-crystal impregnated natural products, co-crystal-impregnated synthetic materials, fertilizers and Feinstverkapselitch in polymeric materials.
  • customary formulations such as solutions, emulsions, wettable powders, water- and oil-based suspensions, powders, dusts, pastes, soluble powders, soluble granules, scattering granules, suspension-emulsion concentrates, co-crystal impregnated natural products, co-crystal-impregnated synthetic materials, fertilizers and Feinstverkapselitch in polymeric materials.
  • formulations are prepared in a known manner, e.g. by mixing the co-crystals according to the invention with extenders, ie liquid solvents and / or solid carriers, if appropriate using surface-active agents, ie emulsifiers and / or dispersants and / or foam-forming agents.
  • extenders ie liquid solvents and / or solid carriers
  • surface-active agents ie emulsifiers and / or dispersants and / or foam-forming agents.
  • Excipients which can be used are those which are suitable for imparting special properties to the composition itself and / or preparations derived therefrom (for example spray liquor, seed dressing), such as certain technical properties and / or specific biological properties.
  • Typical auxiliaries are: extenders, solvents and carriers.
  • polar and non-polar organic chemical liquids e.g. from the classes of aromatic and non-aromatic hydrocarbons (such as paraffins, alkylbenzenes, alkylnaphthalenes, chlorobenzenes), alcohols and polyols (which may also be substituted, etherified and / or esterified), ketones (such as acetone, cyclohexanone), Esters (including fats and oils) and (poly) ethers, simple and substituted amines, amides, lactams (such as N-alkylpyrrolidones) and lactones, sulfones and sulfoxides (such as dimethylsulfoxide).
  • aromatic and non-aromatic hydrocarbons such as paraffins, alkylbenzenes, alkylnaphthalenes, chlorobenzenes
  • alcohols and polyols which may also be substituted, etherified and / or esterified
  • ketones such as
  • Suitable liquid solvents are essentially: aromatics, such as xylene, toluene, or alkylnaphthalenes, chlorinated aromatics and chlorinated aliphatic hydrocarbons, such as chlorobenzenes, chloroethylenes or methylene chloride, aliphatic hydrocarbons, such as cyclohexane or paraffins, e.g.
  • Petroleum fractions mineral and vegetable oils, alcohols such as butanol or glycol and their ethers and esters, ketones such as acetone, methyl ethyl ketone, methyl isobutyl ketone or cyclohexanone, strongly polar solvents such as dimethyl sulfoxide, and water.
  • the carrier means a natural or synthetic, organic or inorganic substance, which may be solid or liquid, with which the active ingredients for better applicability, in particular for application to plants or plant parts or seeds mixed or are connected.
  • the solid or liquid carrier is generally inert and should be useful in agriculture.
  • Solid or liquid carriers are e.g. Ammonium salts and ground natural minerals, such as kaolins, clays, talc, chalk, quartz, attapulgite, montmorillonite or diatomaceous earth and synthetic minerals, such as finely divided silica, alumina and silicates in question.
  • solid carriers for granules in particular e.g. Cracked and fractionated natural rocks such as calcite, marble, pumice, sepiolite, dolomite and synthetic granules of inorganic and organic flours and granules of organic material such as paper, sawdust, coconut shells, corncobs and tobacco stems in question.
  • non-ionic and anionic emulsifiers such as polyoxyethylene fatty acid esters, polyoxyethylene fatty alcohol ethers, e.g. Alkylarylpolyglykolether, alkylsulfonates, alkyl sulfates, arylsulfonates and protein hydrolysates in question.
  • Dispersants used are nonionic and / or ionic substances, e.g. from the classes of alcohol POE and / or POP ethers, acid and / or POP POE esters, alkyl aryl and / or POP POE ethers, fatty and / or POP POE adducts, POE and / or POP polyol derivatives, POE and / or POP sorbitol or sugar adducts, alkyl or aryl sulfates, sulfonates and phosphates or the corresponding PO ether adducts in question.
  • nonionic and / or ionic substances e.g. from the classes of alcohol POE and / or POP ethers, acid and / or POP POE esters, alkyl aryl and / or POP POE ethers, fatty and / or POP POE adducts, POE and / or POP polyol derivatives,
  • oligo- or polymers are e.g. those starting from vinylic monomers, from acrylic acid, from EO and / or PO alone or in combination with e.g. (poly) alcohols or (poly) amines.
  • lignin and its sulfonic acid derivatives, simple and modified celluloses, aromatic and / or aliphatic sulfonic acids and their adducts with formaldehyde can be used.
  • Adhesives such as carboxymethylcellulose, natural and synthetic powdery, granular or latex-type polymers can be used in the formulations, such as gum arabic, polyvinyl alcohol, polyvinyl acetate, as well as natural phospholipids such as cephalins and lecithins and synthetic phospholipids.
  • Dyes such as inorganic pigments, e.g. Iron oxide, titanium oxide, ferrocyan blue and organic dyes such as alizarin, azo and metal phthalocyanine dyes and trace nutrients such as salts of iron, manganese, boron, copper, cobalt, molybdenum and zinc.
  • inorganic pigments e.g. Iron oxide, titanium oxide, ferrocyan blue and organic dyes such as alizarin, azo and metal phthalocyanine dyes and trace nutrients such as salts of iron, manganese, boron, copper, cobalt, molybdenum and zinc.
  • additives may be fragrances, mineral or vegetable optionally modified oils, waxes and nutrients (also trace nutrients), such as salts of iron, manganese, boron, copper, cobalt, molybdenum and zinc.
  • Stabilizers such as cold stabilizers, preservatives, antioxidants, light stabilizers or other chemical and / or physical stability-improving agents may also be present.
  • the content of 4 - ⁇ [(6-chloro-3-yl) methyl] (2,2-difluoroethyl) amino ⁇ furan-2 (5H) -one of the use forms prepared from the formulations can vary widely.
  • the content of 4- ⁇ [(6-chloro-3-yl) methyl] (2,2-difluoroethyl) amino ⁇ furan-2 (5H) -one of the use forms is in the range of 0.00000001 to 97 wt. %, preferably in the range of 0.0000001 to 97% by weight, more preferably in the range of 0.000001 to 83% by weight or 0.000001 to 5% by weight and most preferably in the range of 0, 0001 to 1 wt .-%.
  • the co-crystals according to the invention may optionally be used in certain concentrations or application rates together with herbicides, safeners, growth regulators or agents for improving plant properties, or with microbicides, be fungerra fungicides, in particular antimycotics, bactericides, viricides (including anti-viral agents) or agents against MLO (Mycoplasma-like-organism) and RLO (Rickettsia-like-organism).
  • FIGS. 1 and 2 below show in each case the intensities of an X-ray radiation [I] determined in accordance with the exemplary embodiments over twice the respectively dimensioned diffraction angle [2 ⁇ ].
  • Fig. 1 shows an X-ray diffraction analysis of a powder of the co-crystal of the present invention containing 4 - ⁇ [(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino ⁇ furan-2 (5H) -one and salicylic acid as Co -Former according to Example 2 in conjunction with Example 4.
  • Fig. 2 shows an X-ray diffraction analysis of a powder of the co-crystal of the present invention containing 4 - ⁇ [(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino ⁇ furan-2 (5H) -one and as salicylic acid Co -Former according to Example 3 in conjunction with Example 4.
  • Example 3 shows measured data of a differential calorimetry (DSC) according to example 5, plotted as thermal power (P) of a powder of 4 - ⁇ [(6-chloropyrid-3-yl) methyl] taken up at a temperature (T) (FIG. 2-difluoroethyl) amino ⁇ furan-2 (5H) -one according to Example 1 (A) and a powder from Example 2 (B).
  • DSC differential calorimetry
  • the milled material was dried overnight at room temperature (23 ° C) and ambient pressure (1013 hPa) to evaporate the ethyl acetate. A powder was obtained which was supplied to Examples 4 and 5.
  • Crystals of about 1 mm size were formed overnight at room temperature (23 ° C.) and under ambient pressure (1013 hPa).
  • Example 6 Individual single crystals are removed and fed to the experiment according to Example 6. The remaining crystals are crushed by hand and subjected to a study according to Example 4.
  • Example 4 Powder X-ray diffractometric measurement (p-XRD) of the powder from Examples 2 and 3
  • the powder obtained from Examples 2 and 3 was examined by means of an X-ray diffractometer (Stoe, type STADI-P transmission diffractometer, primary monochromator: Ge [11], radiation source, CU KOL I, wavelength 1.54 ⁇ , detector: linear PSD) , Examination of the powder of Example 2 yielded the characteristic X-ray diffractogram shown in FIG. Examination of the powder of Example 3 yielded the characteristic X-ray diffractogram shown in FIG.
  • X-ray diffractometer Stoe, type STADI-P transmission diffractometer, primary monochromator: Ge [11], radiation source, CU KOL I, wavelength 1.54 ⁇ , detector: linear PSD
  • FIGS. 1 and 2 are X-ray diffractograms of the same substance. Both X-ray diffractograms are of one of the pure substances 4 - ⁇ [(6-chloropyrid-3-yl) methyl] (2,2-) difluoroethyl) amino ⁇ furan-2 (5H) -one and salicylic acid (both not shown here). Accordingly, both inventive methods for producing a Co crystal according to the invention form the same co-crystal.
  • Example 5 Differential calorimetry (DSC) of the powders of Example 2 and of 4 - ⁇ [(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino ⁇ furan-2 (5H) -one
  • DSC Differential calorimetry
  • the melting point of the co-crystal of 4 - ⁇ [(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino ⁇ furan-2 (5H) -one and salicylic acid according to Example 2 is about 85 ° C ,
  • the melting point of the resulting substance is increased.
  • Example 6 X-ray diffraction analysis (XRD) of the single crystal from Example 3
  • the measured data were recorded in all spatial directions, ie the detector was moved completely around the sample by one horizontal and one vertical angle.
  • the measurement data were collected and logged using the software Crysalis (Oxford Diffraction 2007).

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Dentistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Pest Control & Pesticides (AREA)
  • Agronomy & Crop Science (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

The invention relates to new co-crystals of 4-{[(6-chloropyrid-3-yl)methyl]­(2,2-difluoroethyl)amino}furan-2(5H)-one (I) with salicylic acid, and also to processes for preparation thereof and use thereof.

Description

CO-KRISTALL VON  CO CRYSTAL OF
4-{ [ ( 6-CHLORPYRID-3-YL) METHYL] ( 2 , 2-DIFLUORETHYL) AMINO}FURAN-2 (5H) -ON MIT SALIZYLSÄURE UND DESSEN VERWENDUNG ALS PESTIZID  4- {[(6-CHLOROPYRID-3-YL) METHYL] (2, 2-DIFLUORETHYL) AMINO} FURAN-2 (5H) -ONE WITH SALIZYLIC ACID AND THEIR USE AS PESTICIDE
D i e E r fi n d u n g b e t r i fft n e u e C o-Kristalle von 4-{[(6-Chlorpyrid-3-yl)methyl](2,2- difluorethyl)amino}furan-2(5H)-on mit Salizylsäure, sowie Verfahren zu deren Herstellung und deren Verwendung. The invention operates new C o crystals of 4 - {[(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino} furan-2 (5H) -one with salicylic acid, as well as methods for their production and their use.
Die Verbindung 4-[[(6-Chlo^yridin-3-yl)methyl](2,2-difluorethyl)amino]furan-2(5H)-on sowie Methoden zur Herstellung dieser Verbindung sind bekannt. Auch ist bekannt, dass diese Verbindung Insektizide bzw. akarizide Wirkung besitzt. So beschreibt beispielsweise die WO 2007/115644 AI erstmals die Herstellung dieser Verbindung sowie seine Verwendung zur Bekämpfung von Arthropoden, insbesondere Insekten. Die Herstellung der Verbindung wurde weiterhin in WO 2009/036899 AI beschrieben. Es wurde nun festgestellt, dass die mit dem bekannten Verfahren hergestellten Verbindung sich nicht in einer wirtschaftlich relevanten Form anwenden lassen.  The compound 4 - [[(6-chloro-3-yl-yl) methyl] (2,2-difluoroethyl) amino] furan-2 (5H) -one and methods for the preparation of this compound are known. It is also known that this compound has insecticidal or acaricidal activity. For example, WO 2007/115644 A1 describes, for the first time, the preparation of this compound and its use for controlling arthropods, in particular insects. The preparation of the compound was further described in WO 2009/036899 Al. It has now been found that the compound prepared by the known method can not be applied in an economically relevant form.
Es ist bekannt, dass Feststoffe in amorpher und kristalliner Form sowie als Polymorphe, Hydrate und Solvate vorliegen können, die insbesondere physikalische Eigenschaften, wie Löslichkeit, Bioverfügbarkeit bei Aufnahme in einen Organismus, Hygroskopizität und Schmelzpunkt signifikant beeinflussen können. Diese physikalischen Eigenschaften können die Verwendbarkeit des Stoffes in der einen oder anderen Weise einschränken, oder erweitern.  It is known that solids can be present in amorphous and crystalline form as well as polymorphs, hydrates and solvates, which in particular can significantly influence physical properties such as solubility, bioavailability upon ingestion into an organism, hygroscopicity and melting point. These physical properties may limit or extend the utility of the substance in one way or another.
Es ist weiterhin bekannt, dass für einige Polymorphe eine bestimmte Modifikation über den gesamten Temperaturbereich bis zum Schmelzpunkt die thermodynamisch stabile Phase darstellt, wohingegen bei anderen Stoffsystemen ein oder mehrere Übergangspunkte existieren, bei dem sich das Stabilitätsverhältnis umkehrt. Es ist nicht möglich, das Stabilitätsverhältnis und insbesondere die Existenz und Lage von oben bezeichneten Übergangspunkten vorherzusagen. Ein Überblick über den Stand des Wissens zu diesen prinzipiellen thermodynamischen Verhältnissen ist in J. Bernstein, RJ. Davey, J.O. Henck, Angew. Chem. Int. Ed., 1999, 38, 3440-3461 gegeben.  It is further known that for some polymorphs, a particular modification over the entire temperature range up to the melting point represents the thermodynamically stable phase, whereas in other material systems one or more transition points exist in which the stability ratio is reversed. It is not possible to predict the stability ratio and in particular the existence and location of above-mentioned transition points. An overview of the state of knowledge of these principal thermodynamic conditions is given in J. Bernstein, RJ. Davey, J.O. Henck, Angew. Chem. Int. Ed., 1999, 38, 3440-3461.
Das Auftreten von Wirkstoffen in verschiedenen kristallinen Modifikationen ist sowohl für die Ausarbeitung von Herstellungsverfahren als auch für die Entwicklung von Formulierungen von großer Bedeutung. So unterscheiden sich die verschiedenen kristallinen Modifikationen einer chemischen Verbindung neben dem Aussehen (Kristallhabitus) und der Härte auch in zahlreichen weiteren physiko-chemischen Eigenschaften. Dabei können Unterschiede bezüglich der Stabilität, der Filtrierbarkeit, der Mahlbarkeit, der Löslichkeit, der Hygroskopizität, des Schmelzpunktes, der Feststoffdichte und der Fließfähigkeit einen starken Einfluss auf die Qualität und die Wirksamkeit von Pflanzenbehandlungsmitteln ausüben. Es ist bisher nicht möglich, das Auftreten und die Anzahl von kristallinen Modifikationen einschließlich ihrer physiko-chemischen Eigenschaften vorherzusagen. Vor allem die thermodynamische Stabilität und auch das unterschiedliche Verhalten nach Darreichung in lebenden Organismen lassen sich nicht im Voraus bestimmen. The occurrence of active ingredients in various crystalline modifications is of great importance both for the preparation of preparation processes and for the development of formulations. Thus, the various crystalline modifications of a chemical compound differ in appearance (crystal habit) and hardness in numerous other physico-chemical properties. Differences in stability, filterability, grindability, solubility, hygroscopicity, melting point, solid density, and flowability can exert a strong influence on the quality and efficacy of plant treatment agents. It has not been possible to predict the occurrence and number of crystalline modifications, including their physicochemical properties. Above all, the thermodynamic stability and the different behavior after administration in living organisms can not be determined in advance.
Eine weitere kristalline Modifikation eines Feststoffs stellen sogenannte Co-Kristalle dar. Diese umfassen den Feststoff mit sogenannten Co-Formern. Auch hier können vorteilhafte physikalische Eigenschaften gegenüber dem ursprünglichen Feststoff erhalten werden.  Another crystalline modification of a solid is so-called co-crystals. These include the solid with so-called co-formers. Again, advantageous physical properties over the original solid can be obtained.
So beschreibt beispielsweise die WO 2008/013823 A2 ein Verfahren zur Herstellung eines Co- K r i s t a l l s u m f a s s e n d ( 2 R-trans)-6-chloro-5[[4-[(4-fluorophenyl)methyl]-2,5-dimethyl-l- piperazinyl]carbonyl]-N,N, l-trimethyl-alpha-oxo-lH-indol-3-acetamid oder dessen Hydrochlorid oder dessen freie Base und einen Co-Former, der Arginin, Urea, Salicylsäure, 4-Amino-Salicylsäure und Benzoesäure sein kann. Die offenbarten Co-Kristalle können auch mehr als einen Co-Former enthalten. Das stöchiometrische Verhältnis in dem kristalliner Feststoff und Co-Former zu einander vorliegen können, kann 1 :1, 2: 1 oder 1 :2 betragen. Es wird weiterhin beschrieben, dass die gefundenen Co-Kristalle eine vorteilhafte Löslichkeit, Lösungsgeschwindigkeit, Bioverfügbarkeit, Stabilität und Weiterverarbeitbarkeit aufweisen.  For example, WO 2008/013823 A2 describes a process for the preparation of a carboxyl radical comprising (2R-trans) -6-chloro-5 [[4 - [(4-fluorophenyl) methyl] -2,5-dimethyl-1 - piperazinyl] carbonyl] -N, N, 1-trimethyl-alpha-oxo-1H-indole-3-acetamide or its hydrochloride or its free base and a co-former, arginine, urea, salicylic acid, 4-amino-salicylic acid and benzoic acid. The disclosed co-crystals may also contain more than one co-former. The stoichiometric ratio in the crystalline solid and co-former to each other may be 1: 1, 2: 1 or 1: 2. It is further described that the co-crystals found have advantageous solubility, dissolution rate, bioavailability, stability and processability.
Das in der WO 2008/013823 A2 offenbarte Verfahren zur Herstellung der Co-Kristalle kann durch Mahlen des kristallinen Feststoffs gemeinsam mit dem mindestens einen Co-Former oder gemeinsames Schmelzen des kristallinen Feststoffs mit dem mindestens einen Co-Former, oder alternativ durch gemeinsames Auflösen von kristallinem Feststoff mit dem mindestens einen Co- Former und nachfolgendes Kristallisieren gekennzeichnet sein. Hierbei können die kristalline Substanz und der mindestens eine Co-Former in einem stöchiomerischen Verhältnis von 1 :1 bis 1 :100 zu einander vorliegen. Das vorgenannte Mahlen des kristallinen Feststoffs gemeinsam mit dem mindestens einen Co-Former kann auch zusammen mit einer geringen Menge an Lösungsmittel durchgeführt werden. The process disclosed in WO 2008/013823 A2 for the preparation of the co-crystals may be carried out by milling the crystalline solid together with the at least one co-former or co-melting of the crystalline solid with the at least one co-former, or alternatively by co-dissolving crystalline solid may be characterized with the at least one co-former and subsequent crystallization. Here, the crystalline substance and the at least one co-former may be present in a stoichiometric ratio of 1: 1 to 1: 100 to each other. The aforementioned milling of the crystalline solid together with the at least one co-former may also be carried out together with a small amount of solvent.
Die in der WO 2008/013823 A2 offenbarten Verfahren und Vorrichtungen zur Charakterisierung des entstandenen Co-Kristalls umfassen Thermogravimetrische Analyse (TGA), Pulver- Röntgendiffraktometrische Messungen (p-XRD) und Differentielle Kalorimetrie (DSC).  The methods and devices for characterizing the resulting co-crystal disclosed in WO 2008/013823 A2 include thermogravimetric analysis (TGA), powder X-ray diffractometric measurements (p-XRD) and differential calorimetry (DSC).
Die WO 2008/013823 A2 offenbart keinen Co-Kristall umfassend 4-{[(6-Chlorpyrid-3-yl)methyl](2,2- difluorethyl)amino}furan-2(5H)-on. Weiter offenbart die WO 2008/013823 A2 zwar, dass es im Allgemeinen möglich ist, dass sich Co-Kristalle eines kristallinen Feststoffes durch eine Verbesserung der zuvor genannten physikalischen Eigenschaften auszeichnen können, allerdings wird dies im Zusammenhang mit den in der WO 2008/013823 A2 offenbarten Co-Kristallen nicht dargelegt. Es erscheint weiter zweifelhaft, ob die offenbarten Co-Kristalle tatsächlich existent sind. Es werden lediglich Hinweise offenbart, dass die Co-Kristalle existieren könnten. Ein schlussendlicher Beweis, durch die Züchtung eines Einkristalls und dessen Messung wird nicht offenbart. Die offenbarten Pulver- Röntgendiffraktometrischen Messungen können durch Beugung und Brechung an den Partikeloberflächen auch Fehlinformationen transportieren. WO 2008/013823 A2 does not disclose a co-crystal comprising 4 - {[(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino} furan-2 (5H) -one. Although WO 2008/013823 A2 discloses that it is generally possible that co-crystals of a crystalline solid may be distinguished by an improvement in the abovementioned physical properties, this is in connection with the processes described in WO 2008/013823 A2 disclosed co-crystals are not disclosed. It also seems doubtful whether the disclosed co-crystals actually exist. Only hints are disclosed that the co-crystals could exist. A final proof, by the cultivation of a single crystal and its measurement is not revealed. The revealed Powder X-ray diffractometric measurements can also convey misinformation by diffraction and refraction at the particle surfaces.
In der US 2007/0212683 AI wird ein Co-Kristall von VX-950, einem Hepatitis-C-Virus Inhibitor unter anderem mit Oxalsäure offenbart.  US 2007/0212683 A1 discloses a co-crystal of VX-950, a hepatitis C virus inhibitor with, inter alia, oxalic acid.
Ähnlich zur Offenbarung der WO 2008/013823 A2 wird auch hier allgemein offenbart, dass die erhaltenen Co-Kristalle vorteilhafte physikalische Eigenschaften haben können. Es wird zwar eine Stabilitätsmessung eine Suspension des Co-Kristalls offenbart, eine vergleichende Offenbarung zwischen dem reinen kristallinen Feststoff und den Co-Kristallen kann jedoch nicht gefunden werden. Darüber hinaus ist auch in der Offenbarung der US 2007/0212683 AI die Existenz der offenbarten Co-Kristalle gegebenenfalls zu bezweifeln, da auch hier lediglich Pulver-Röntgendiffraktometrische Messungen mit den aus Ihnen resultierenden Fehlerquellen durchgeführt wurden. Similar to the disclosure of WO 2008/013823 A2, it is also generally disclosed here that the resulting co-crystals can have advantageous physical properties. Although a stability measurement of a suspension of the co-crystal is disclosed, a comparative disclosure between the pure crystalline solid and the co-crystals can not be found. In addition, the existence of the disclosed co-crystals may also be doubtful in the disclosure of US 2007/0212683 Al, since in this case too only powder X-ray diffractometric measurements were carried out with the error sources resulting from them.
In der WO 2008/096005 AI wird Thiophanat-methyl als Co-Former für agrochemisch wirksame Stoffe beschrieben, die mindestens eine funktionelle Gruppe umfassen müssen, die als Wasserstoffakzeptor einer Wasserstoffbrückenbindung wirkt.  WO 2008/096005 AI describes thiophanate-methyl as a co-former for agrochemically active substances which must comprise at least one functional group which acts as a hydrogen acceptor of a hydrogen bond.
Im Gegensatz zu WO 2008/013823 A2 und US 2007/0212683 AI werden in WO 2008/096005 AI Einkristalle einiger Co-Kristalle nachgewiesen. Ein Einkristall eines Co-Kristalls umfassend 4-{[(6- Chlorpyrid-3-yl)methyl](2,2-difluorethyl)amino}furan-2(5H)-on ist jedoch nicht beschrieben. Es wird zugleich offenbart, dass die Bildung solcher Co-Kristalle weder maßgeschneidert, noch vorhergesagt werden kann. Es ist daher davon auszugehen, dass die Offenbarung der WO 2008/096005 AI , wie auch die der WO 2008/013823 A2 und US 2007/0212683 AI und weiterer Stand der Technik, der ni c ht d a s V o rh an d e n s e in e in e s C o-Kristalls von 4-{[(6-Chlorpyrid-3-yl)methyl](2,2- difluorethyl)amino}furan-2(5H)-on mittels des Nachweises eines Einkristalls offenbart, einen Co- Kri st a l l v on 4-{[(6-Chlo^yrid-3-yl)methyl](2,2-difluorethyl)amino} furan-2(5H)-on nicht vorwegnehmen oder nahelegen kann. In contrast to WO 2008/013823 A2 and US 2007/0212683 Al, single crystals of some co-crystals are detected in WO 2008/096005 A1. However, a single crystal of a Co crystal comprising 4 - {[(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino} furan-2 (5H) -one is not described. It is also disclosed that the formation of such co-crystals can neither be tailored nor predicted. It can therefore be assumed that the disclosure of WO 2008/096005 A1, as well as those of WO 2008/013823 A2 and US 2007/0212683 Al and further prior art, does not mention the law of the invention in e It discloses C o crystal of 4 - {[(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino} furan-2 (5H) -one by means of detection of a single crystal, a co-crystal allv on 4 - {[(6-Chloro-3-yl) methyl] (2,2-difluoroethyl) amino} furan-2 (5H) -one can not anticipate or suggest.
Ausgehend von diesem Stand der Technik und den hierin gefundenen Mängeln, besteht also die Aufgabe einen Co-Kristall bereitzustellen der die physikalischen Eigenschaften von 4- {[(6- Chlorpyrid-3-yl)methyl](2,2-difluorethyl)amino}furan-2(5H)-on derart verändert, so dass oben genannte Vorteile erhalten werden. Based on this prior art and the deficiencies found herein, it is therefore an object to provide a co-crystal which has the physical properties of 4- {[(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino} Furan-2 (5H) -one changed so that the above benefits are obtained.
Es wurde nun als erster Gegenstand dieser Erfindung überraschend gefunden, dass ein Co-Kristall umfassend 4-{[(6-Chlorpyrid-3-yl)methyl](2,2-difluorethyl)amino}furan-2(5H)-on, der dadurch gekennzeichnet ist, dass er als Co-Former Salizylsäure enthält, diese Aufgabe zu lösen vermag.  It has now surprisingly been found, as a first subject of this invention, that a co-crystal comprising 4 - {[(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino} furan-2 (5H) -one, which is characterized in that it contains salicylic acid as a co-former, is able to solve this task.
Im Zusammenhang mit der vorliegenden Erfindung bezeichnet Co-Kristall einen bei Raumtemperatur (23°C) und Umgebungsdruck (1013 hPa) festen Stoff, der in seinem Kristallgitter mindestens zwei durch Wasserstoffbrückenbindung mit einander in Wechselwirkung stehende Reinsubstanzen enthält, wobei alle im Kristallgitter vorliegenden Reinsubstanzen bei Raumtem eratur (23 °C) und Umgebungsdruck (1013 hPa) ebenfalls Feststoffe sind. In the context of the present invention, co-crystal means a solid substance at room temperature (23 ° C) and ambient pressure (1013 hPa) containing in its crystal lattice at least two hydrogen bonds with interacting pure substances, wherein all pure substances present in the crystal lattice are also solids at room temperature (23 ° C) and ambient pressure (1013 hPa).
Der Begriff Co-Former, wie er im Zusammenhang mit der vorliegenden Erfindung verwendet wird, bezeichnet eine Reinsubstanz, die nicht 4-{[(6-Chlorpyrid-3-yl)methyl](2,2-difluorethyl)amino}furan- 2(5H)-on ist und die zusammen mit 4-{[(6-Chlo^yrid-3-yl)methyl](2,2-difluorethyl)amino} furan- 2(5H)-on in mindestens einem stöchiometrischen Verhältnis ein Adukt bildet, das nur einen Schmelzpunkt hat.  The term co-former, as used in connection with the present invention, denotes a pure substance which is not 4 - {[(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino} furan-2 (5H) -one and which together with 4 - {[(6-chloro-3-yl-yl) methyl] (2,2-difluoroethyl) amino} furan-2 (5H) -one are in at least a stoichiometric ratio Adukt forms, which has only one melting point.
4-{[(6-Chlorpyrid-3-yl)methyl](2,2-difluorethyl)amino}furan-2(5H)-on bezeichnet im Zusammenhang mit der vorliegenden Erfindung alle Polymorphe, Solvate und auch Hydrate des Stoffs gemäß Formel (I):  4 - {[(6-Chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino} furan-2 (5H) -one in the context of the present invention denotes all polymorphs, solvates and also hydrates of the substance according to formula (I):
Der erfindungsgemäße Co-Kristall hat üblicherweise einen gegenüber der Reinsubstanz 4-{[(6- Chlorpyrid-3-yl)methyl](2,2-difluorethyl)amino}furan-2(5H)-on erhöhten Schmelzpunkt.  The co-crystal according to the invention usually has a melting point which is higher than that of the pure substance 4 - {[(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino} furan-2 (5H) -one.
Als Schmelzpunkt wird im Zusammenhang mit der vorliegenden Erfindung jene Temperatur verstanden, bei der die Substanz bei Messung des Schmelzpunktes in einer differentiellen Kalorimetrie (DSC) die höchste Wärmeabgabe aufweist. Das Schmelzen der Substanz setzt bereits früher ein, als bei jener Temperatur, bei der die vorgenannte höchste Wärmeabgabe zu messen ist und endet üblicherweise auch bei höheren Temperaturen, weshalb die im Folgenden angegebenen Schmelzpunkte nach anderen Definitionen des Schmelzpunktes durchaus auch bei niedrigeren oder höheren Temperaturen liegen können.  In the context of the present invention, the term melting point is understood as the temperature at which the substance has the highest heat output when measuring the melting point in a differential calorimetry (DSC). Melting of the substance begins earlier than at the temperature at which the aforementioned highest heat output is to be measured and usually ends at higher temperatures, which is why the below-mentioned melting points according to other definitions of the melting point quite well at lower or higher temperatures can.
Der erhöhte Schmelzpunkt des erfindungsgemäßen Co-Kristalls ist besonders vorteilhaft, weil der Co- Kristall im Gegensatz zum Reinstoff 4-{[(6-Chlorpyrid-3-yl)methyl](2,2-difluorethyl)amino}furan- 2(5H)-on bei höheren Temperaturen behandelt werden kann, ohne zu schmelzen.  The increased melting point of the co-crystal according to the invention is particularly advantageous because the Co crystal, in contrast to the pure substance 4 - {[(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino} furan-2 (5H ) -one can be treated at higher temperatures without melting.
Ein solches Behandeln bei höheren Temperaturen kann ein Trocknen im Zuge des Herstellens des Co- Kristalls sein, oder auch ein Lagern unter erhöhten Temperaturen.  Such treatment at higher temperatures may be drying in the course of producing the co-crystal, or else storage at elevated temperatures.
Insbesondere zeigt der erfindungsgemäße Co-Kristall eine verbesserte Lagerstabilität, da er beim Lagern unter erhöhten Temperaturen nicht dazu neigt, an seiner Oberfläche anzuschmelzen und somit zu agglomerieren oder an der Wand des Transportbehälters, in dem er transportiert wird, anzuhaften. Weiterhin hat der erfindungsgemäße Co-Kristall üblicherweise eine gegenüber der Reinsubstanz 4- {[(6-Chlorpyrid-3-yl)methyl](2,2-difluorethyl)amino}furan-2(5H)-on erhöhte Löslichkeit in Wasser.In particular, the co-crystal according to the invention exhibits improved storage stability since, when stored at elevated temperatures, it does not tend to melt on its surface and thus agglomerate or adhere to the wall of the transport container in which it is transported. In addition, the co-crystal according to the invention usually has a higher solubility in water than the pure substance 4 {[(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino} furan-2 (5H) -one.
Eine erhöhte Löslichkeit in Wasser ist insbesondere dann vorteilhaft, wenn das 4-{[(6-Chlorpyrid-3- yl)methyl](2,2-difluorethyl)amino} furan-2(5H)-on bei seiner Verwendung versprüht werden soll. Es lassen sich somit höher konzentrierte Lösungen von 4-{[(6-Chlorpyrid-3-yl)methyl](2,2- difluorethyl)amino}furan-2(5H)-on herstellen, die dementsprechend wirksamer sind. An increased solubility in water is particularly advantageous if the 4 - {[(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino} furan-2 (5H) -one is to be sprayed during its use , It is thus possible to prepare more highly concentrated solutions of 4 - {[(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino} furan-2 (5H) -one which are correspondingly more effective.
In einer ersten bevorzugten Weiterentwicklung des erfindungsgemäßen Co-Kristalls, besteht der Co- Kristall im Wesentlichen aus 4-{[(6-Chlo^yrid-3-yl)methyl](2,2-difluorethyl)amino} furan-2(5H)-on und Salizylsäure als Co-Former.  In a first preferred development of the co-crystal of the invention, the Co crystal consists essentially of 4 - {[(6-chloro-3-yl-yl) methyl] (2,2-difluoroethyl) amino} furan-2 (5H ) -one and salicylic acid as co-formers.
Der Schmelzpunkt des erfindungsgemäßen Co-Kristalls liegt üblicherweise im Bereich von 70°C bis 90°C, erfindungsgemäße Co-Kristalle mit einem Schmelzpunkt von etwa 82°C sind bevorzugt.  The melting point of the co-crystal according to the invention is usually in the range of 70 ° C to 90 ° C, co-crystals according to the invention having a melting point of about 82 ° C are preferred.
Der vorgenannte Schmelzpunkt kann in allgemein bekannter Art und Weise durch differentielle Kalorimetrie (DSC) ermittelt werden.  The aforementioned melting point can be determined in a well-known manner by differential calorimetry (DSC).
Üblicherweise beträgt das stöchiometrische Verhältnis von 4-{[(6-Chlorpyrid-3-yl)methyl](2,2- difluorethyl)amino} furan-2(5H)-on zu Salizylsäure in der ersten bevorzugten Weiterentwicklung 1 :1. Typically, the stoichiometric ratio of 4 - {[(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino} furan-2 (5H) -one to salicylic acid in the first preferred embodiment is 1: 1.
Der erfindungsgemäße Co-Kristall gemäß der ersten bevorzugten Weiterentwicklung ist weiter dadurch gekennzeichnet, dass er eine monokline Morphologie aufweist. Hierbei weist der Co-Kristall üblicherweise die Raumgruppe P2(l)/n gemäß Cambridge Strukturdatenbank (F. FL, Allen, Acta Cryst.B58, (2002) 380-388) auf. The co-crystal according to the first preferred embodiment of the present invention is further characterized as having a monoclinic morphology. Here, the co-crystal usually has the space group P2 (I) / n according to Cambridge structure database (FL, Allen, Acta Cryst.B58, (2002) 380-388).
Die vorgenannte Morphologie und Raumgruppe, wie auch das vorstehend erwähnte stöchiometrische Verhältnis von 4-{[(6-Chlorpyrid-3-yl)methyl](2,2-difluorethyl)amino}furan-2(5H)-on zu Salizylsäure kann in allgemein bekannter Art und Weise durch Röntgenbeugungsanalyse eines Einkristalls des Co- Kristalls ermittelt werden.  The aforementioned morphology and space group, as well as the above-mentioned stoichiometric ratio of 4 - {[(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino} furan-2 (5H) -one to salicylic acid can be found in in a generally known manner by X-ray diffraction analysis of a single crystal of the Co crystal.
Ein weiterer Gegenstand der vorliegenden Erfindung ist ein erstes Verfahren zur Herstellung eines Co- Kristalls umfassend 4-{[(6-Chlorpyrid-3-yl)methyl](2,2-difluorethyl)amino}furan-2(5H)-on, dadurch gekennzeichnet, dass es mindestens die Schritte  A further subject of the present invention is a first process for preparing a cocrystal comprising 4 - {[(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino} furan-2 (5H) -one, characterized in that it comprises at least the steps
a) Vermengen von 4-{[(6-Chlo^yrid-3-yl)methyl](2,2-difluorethyl)amino}furan-2(5H)-on mit Salizylsäure erhaltend eine Mischung A,  a) mixing 4 - {[(6-chloro-3-yl-yl) methyl] (2,2-difluoroethyl) amino} furan-2 (5H) -one with salicylic acid to obtain a mixture A,
b) gegebenenfalls weiteres Vermengen der Mischung A mit einem Lösungsmittel erhaltend eine Mischung A' und  b) optionally further mixing the mixture A with a solvent containing a mixture A 'and
c) Mahlen von Mischung A oder Mischung A' erhaltend den erfindungsgemäßen Co-Kristall umfasst. Das Vermengen gemäß Schritt a) des erfindungsgemäßen Verfahrens kann geschehen indem entweder 4-{[(6-Chlo^yrid-3-yl)methyl](2,2-difluorethyl)amino}furan-2(5H)-on v o rg e l e g t w i r d un d Salizylsäure zugegeben wird, oder umgekehrt. B evorzugt wird das 4-{[(6-Chlorpyrid-3- yl)methyl](2,2-difluorethyl)amino}furan-2(5H)-on vorgelegt und Salizylsäure unter Wiegen zudosiert. Die gemäß dem Schritt a) des erfindungsgemäßen Verfahrens erhaltene Mischung A kann 4-{[(6- Chlo^yrid-3-yl)methyl](2,2-difluorethyl)amino}furan-2(5H)-on und Salizylsäure in beliebigen stöchiometrischen Verhältnissen enthalten. c) milling mixture A or mixture A 'containing the co-crystal according to the invention comprises. The blending according to step a) of the process according to the invention can be carried out by either 4 - {[(6-chloro-3-yl-3-yl) methyl] (2,2-difluoroethyl) amino} furan-2 (5H) -one and salicylic acid is added, or vice versa. Preferably, the 4 - {[(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino} furan-2 (5H) -one is initially introduced and salicylic acid is added by weighing. The mixture A obtained in step a) of the process according to the invention may comprise 4 - {[(6-chloro-3-yl) methyl] (2,2-difluoroethyl) amino} furan-2 (5H) -one and salicylic acid contain any stoichiometric ratios.
Für die Herstellung der ersten bevorzugten Weiterentwicklung des erfindungsgemäßen Co-Kristalls, enthält die Mischung A bevorzugt 4-{[(6-Chlorpyrid-3-yl)methyl](2,2-difluorethyl)amino}furan- 2(5H)-on in einem stöchiometrischen Verhältnis von 1 : 1 zu Salizylsäure.  For the preparation of the first preferred further development of the co-crystal according to the invention, the mixture A preferably contains 4 - {[(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino} furan-2 (5H) -one in a stoichiometric ratio of 1: 1 to salicylic acid.
Hieraus ergibt sich auch die bevorzugte Verfahrensweise des Zudosierens der Salizylsäure zu 4-{[(6- Chlorpyrid-3-yl)methyl](2,2-difluorethyl)amino}furan-2(5H)-on unter Wiegen. Mit dieser Verfahrensweise kann in besonders exakter Weise das vorgenannte stöchiometrische Verhältnis zu 4- {[(6-Chlo^yrid-3-yl)methyl](2,2-difluorethyl)amino}furan-2(5H)-on eingestellt werden, so dass sich der Co-Kristall gemäß der ersten bevorzugten Weiterentwicklung mit seinen besonders vorteilhaften Eigenschaften bevorzugt bildet.  This also results in the preferred procedure of adding salicylic acid to 4 - {[(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino} furan-2 (5H) -one under weighing. With this procedure, the aforesaid stoichiometric ratio to 4- {[(6-chloro-3-yl-3-yl) -methyl] (2,2-difluoroethyl) -amino} -furan-2 (5H) -one can be adjusted in a particularly exact manner. so that the co-crystal preferably forms according to the first preferred development with its particularly advantageous properties.
In einer bevorzugten Ausführungsform des Verfahrens, wird das Vermengen gemäß dem Schritt b) ausgeführt.  In a preferred embodiment of the method, the mixing according to step b) is carried out.
Das gemäß Schritt b) des erfindungsgemäßen Verfahrens verwendete Lösungsmittel kann jedes geeignete Lösungsmittel sein, das dazu in der Lage ist mindestens einen der Stoffe Salizylsäure und/oder 4-{[(6-Chlorpyrid-3-yl)methyl](2,2-difluorethyl)amino}furan-2(5H)-on in einer Konzentration von mindestens 0,01 g/1 zu lösen. Geeignete Lösungsmittel sind insbesondere Aceton, Ethylacetat, Ethanol und 2-Propanol und Mischungen davon.  The solvent used according to step b) of the process according to the invention may be any suitable solvent which is capable of at least one of the substances salicylic acid and / or 4 - {[(6-chloropyrid-3-yl) methyl] (2,2-) difluoroethyl) amino} furan-2 (5H) -one in a concentration of at least 0.01 g / 1. Suitable solvents are in particular acetone, ethyl acetate, ethanol and 2-propanol and mixtures thereof.
Im Schritt b) des erfindungsgemäßen Verfahrens wird das Lösungsmittel in einer Menge zugegeben, so dass in der resultierenden Mischung A' die Löslichkeitskonzentration (Löslichkeit) von 4-{[(6- Chlorpyrid-3-yl)methyl](2,2-difluorethyl)amino}furan-2(5H)-on und/oder Salizylsäure überschritten wird. Bevorzugt wird die Löslichkeitskonzentration von 4-{[(6-Chlorpyrid-3-yl)methyl](2,2- difluorethyl)amino}furan-2(5H)-on und Salizylsäure überschritten. Das ist besonders vorteilhaft, weil hierdurch die Feststoffe im Wesentlichen weiter als Feststoffe vorliegen und lediglich die Oberflächen der Feststoffe mit dem Lösungsmittel benetzt sind. Hierdurch wird der molekulare Kontakt zwischen dem 4-{[(6-Chlorpyrid-3-yl)methyl](2,2-difluorethyl)amino}furan-2(5H)-on und dem Co-Former Salizylsäure verbessert, ohne dass die Wahrscheinlichkeit der Bildung von Solvaten und/oder Hydraten überproportional erhöht wird. Weiter kann hierdurch die Anwesenheit des Lösungsmittels nicht der molekularen Aduktbildung im Sinne einer Wasserstoffbrückenbindung zwischen 4- {[(6- Chlo^yrid-3-yl)methyl](2,2-difluorethyl)amino}furan-2(5H)-on und dem jeweiligen Co-Former signifikant entgegenstehen. In step b) of the process according to the invention, the solvent is added in an amount such that in the resulting mixture A 'the solubility concentration (solubility) of 4 - {[(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl ) amino} furan-2 (5H) -one and / or salicylic acid is exceeded. Preferably, the solubility concentration of 4 - {[(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino} furan-2 (5H) -one and salicylic acid is exceeded. This is particularly advantageous because it substantially exposes the solids to solids and only wets the surfaces of the solids with the solvent. This improves the molecular contact between the 4 - {[(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino} furan-2 (5H) -one and the co-former salicylic acid without the Probability of formation of solvates and / or hydrates is disproportionately increased. Furthermore, the presence of the solvent can not prevent the formation of molecular adducts in the sense of hydrogen bonding between 4- {[(6- Chlo ^ yrid-3-yl) methyl] (2,2-difluoroethyl) amino} furan-2 (5H) -one and the respective co-former significantly.
Das Mahlen der Mischung A oder Mischung A' kann in allen dem Fachmann allgemein bekannten zum Mahlen von Feststoffen geeigneten Vorrichtungen erfolgen.  Milling of mixture A or mixture A 'may be carried out in any apparatus known to those skilled in the art for grinding solids.
Nicht abschließende Beispiele für Vorrichtungen in denen ein solches Mahlen ausgeführt werden kann sind etwa Mörsermühlen, Schwingmühlen oder Kugelmühlen. Bevorzugt wird Schritt c) des erfindungsgemäßen Verfahrens in Schwingmühlen oder Kugelmühlen ausgeführt. Non-exhaustive examples of devices in which such grinding can be carried out are, for example, mortar mills, vibrating mills or ball mills. Preferably, step c) of the process according to the invention is carried out in vibratory mills or ball mills.
Bei solchen Mahlverfahren muss die in das zu mahlende Material eingetragene Energie so bemessen werden, dass es nicht zu einer ungewollten Ausbildung von amorphen Phasen der Feststoffe kommt, zugleich aber ein intensives in Kontaktbringen der Feststoffe in der Mahlvorrichtung stattfindet. Somit gibt es einen nach oben und unten begrenzten Bereich solcher Energien, wie sie mittels der Mahlvorrichtung in die Feststoffe eingebracht werden kann.  In such grinding processes, the energy introduced into the material to be ground must be sized so as not to result in the unwanted formation of amorphous phases of the solids, but at the same time intensive contacting of the solids in the milling apparatus takes place. Thus, there is an up and down limited range of such energies as can be introduced into the solids by means of the grinder.
Der Fachmann kennt geeignete Parameter mit denen er diese Energie einstellen kann. Hierzu gehören etwa die Dauer und Intensität (z.B. Anpressdruck einer Mörsermühle oder Größe und Material, sowie Amplitude und Frequenz bei einer Schwingmühle oder Drehgeschwindigkeit bei einer Kugelmühle) des Mahlens.  The person skilled in the art knows suitable parameters with which he can set this energy. These include, for example, the duration and intensity (for example, the impact pressure of a mortar mill or size and material, as well as the amplitude and frequency in a vibratory mill or rotational speed in a ball mill) of grinding.
Solche Verfahrensweisen sind besonders vorteilhaft, weil durch die Begrenzung der eingetragenen Energie sichergestellt werden kann, dass hinsichtlich des Mindestmaßes an Energie ein Mindestmaß an intensivem mit einander in Kontakt bringen von 4-{[(6-Chlorpyrid-3-yl)methyl](2,2- difluorethyl)amino}furan-2(5H)-on mit dem Co-Former Salizylsäure erfolgt, während zugleich durch die Begrenzung nach oben ein zu intensives Beanspruchen der Stoffe vermieden wird. Ein solches zu intensives Beanspruchen der Stoffe, die gemahlen werden, kann dazu führen, dass diese in einen amorphen Zustand überführt werden, was die Bildung eines Co-Kristalls eventuell verhindert, bzw. einen gebildeten Co-Kristall zerstören kann.  Such procedures are particularly advantageous because, by limiting the energy input, it is possible to ensure that a minimum of intense exposure of 4 - {[(6-chloropyrid-3-yl) methyl] (2 , 2-difluoroethyl) amino} furan-2 (5H) -one is carried out with the co-former salicylic acid, while at the same time avoiding excessive stress on the substances due to the limitation to the top. Such excessive stress on the materials being ground may cause them to be converted to an amorphous state, possibly preventing the formation of a co-crystal or destroying a formed co-crystal.
Das gesamte Verfahren wird üblicherweise bei Raumtemperatur (23°) und Umgebungsdruck (1013 hPa) ausgeführt. Es kann jedoch zweckmäßig sein das Verfahren und insbesondere den Schritt c) bei niedrigeren Temperaturen auszuführen, um eine gewisse Erwärmung der zu mahlenden Stoffe tolerieren zu können, ohne dass der Energie eintrag in vorgenannter Überführung in den amorphen Zustand resultiert. The entire process is usually carried out at room temperature (23 °) and ambient pressure (1013 hPa). However, it may be appropriate to carry out the process and in particular the step c) at lower temperatures in order to tolerate some heating of the materials to be ground can, without the energy entry results in the aforementioned transfer to the amorphous state.
Ein weiterer Gegenstand der vorliegenden Erfindung ist ein zweites Verfahren zur Herstellung eines Co-Kristalls umfassend 4-{[(6-Chlorpyrid-3-yl)methyl](2,2-difluorethyl)amino} furan-2(5H)-on, dadurch gekennzeichnet, dass es mindestens die Schritte a) Bereitstellen einer gesättigten Lösung (A) von 4-{[(6-Chlorpyrid-3-yl)methyl](2,2- difluorethyl)amino}furan-2(5H)-on und/oder einer gesättigten Lösung (B) von Salizylsäure, und A further subject of the present invention is a second process for preparing a cocrystal comprising 4 - {[(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino} furan-2 (5H) -one, characterized in that it comprises at least the steps a) providing a saturated solution (A) of 4 - {[(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino} furan-2 (5H) -one and / or a saturated solution (B ) of salicylic acid, and
b) Vermengen von Lösungen (A) und (B) und/oder oder Hinzugeben von Salizylsäure als Feststoff z u d er Lösung (A) und/oder Hinzugeben von 4-{[(6-Chlorpyrid-3- yl)methyl](2,2-difluorethyl)amino} furan-2(5H)-on als Feststoff zu der Lösung (B) umfasst.  b) mixing solutions (A) and (B) and / or adding salicylic acid as a solid to give solution (A) and / or adding 4 - {[(6-chloropyrid-3-yl) methyl] (2, 2-difluoroethyl) amino} furan-2 (5H) -one as a solid to the solution (B).
Gemäß dem vorstehenden zweiten erfindungsgemäßen Verfahren kann die Lösung (A) mit einem ersten Lösungsmittel hergestellt und die Lösung (B) mit einem zweiten Lösungsmittel hergestellt werden.  According to the above second method of the invention, the solution (A) can be prepared with a first solvent and the solution (B) can be prepared with a second solvent.
Das erste und das zweite Lösungsmittel können unabhängig von einander ausgewählt sein, aus einer Liste bestehend aus Aceton, Ethylacetat, Ethanol, 2-Propanol und Wasser oder Gemische davon. The first and second solvents may be independently selected from a list consisting of acetone, ethyl acetate, ethanol, 2-propanol and water or mixtures thereof.
In bevorzugten Ausführungsformen sind das erste und das zweite Lösungsmittel das Gleiche. In preferred embodiments, the first and second solvents are the same.
Gemäß dem Schritt a) des zweiten erfindungsgemäßen Verfahrens kann auch nur eine Lösung (A) oder eine Lösung (B) vorliegen. Wenn nur eine Lösung (A) oder eine Lösung (B) gemäß dem Schritt a) des Verfahrens bereitgestellt wird, so wird im Schritt b) entweder zu der Lösung (A) Salizylsäure als Feststoff hinzugegeben oder zu der Lösung (B) 4-{[(6-Chlorpyrid-3-yl)methyl](2,2- difluorethyl)amino}furan-2(5H)-on als Feststoff hinzugegeben.  According to step a) of the second process according to the invention, only one solution (A) or one solution (B) may also be present. If only one solution (A) or one solution (B) is provided according to the step a) of the method, then in step b) either salicylic acid as a solid is added to the solution (A) or to the solution (B) 4- { Added [(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino} furan-2 (5H) -one as a solid.
Es ist in alternativen Ausführungsformen des zweiten erfindungsgemäßen Verfahrens auch möglich eine Lösung (A) und eine Lösung (B) gemäß dem Schritt a) bereit zu stellen und diese gemäß dem Schritt b) des Verfahrens zu vermengen, während man zu den sich vermengenden Lösungen (A) und (B) auch noch Salizylsäure als Feststoff und/oder 4-{[(6-Chlorpyrid-3-yl)methyl](2,2- difluorethyl)amino}furan-2(5H)-on als Feststoff hinzu gibt.  It is also possible in alternative embodiments of the second process according to the invention to provide a solution (A) and a solution (B) according to step a) and to mix them according to step b) of the process, while adding to the intermingling solutions ( A) and (B) also add salicylic acid as a solid and / or 4 - {[(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino} furan-2 (5H) -one as a solid ,
Bevorzugt wird das zweite erfindungsgemäße Verfahren so ausgeführt, dass im Schritt a) die Lösungen (A) und (B) bereitgestellt werden und diese Lösungen ohne Zugabe von weiterem Feststoff mit einander vermengt werden.  The second process according to the invention is preferably carried out such that in step a) the solutions (A) and (B) are provided and these solutions are mixed with one another without the addition of further solid.
Ein weiterer Gegenstand der vorliegenden Erfindung ist die Verwendung der erfindungsgemäßen Co- Kristalle von 4-{[(6-Chlorpyrid-3-yl)methyl](2,2-difluorethyl)amino}furan-2(5H)-on mit Salizylsäure als Co-Former zur Bekämpfung von tierischen Schädlingen, insbesondere von Insekten, Spinnentieren und/oder Nematoden, die in der Landwirtschaft, in den Forsten, im Vorrats- und Materialschutz sowie auf dem Hygienesektor vorkommen.  Another object of the present invention is the use of co-crystals of 4 - {[(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino} furan-2 (5H) -one invention with salicylic acid as Co-formers for combating animal pests, in particular insects, arachnids and / or nematodes, which are found in agriculture, in forests, in the protection of stored products and materials and in the hygiene sector.
Im Bereich der Landwirtschaft und in den Forsten, können im Rahmen der Verwendung der erfindungsgemäßen Co-Kristalle alle Pflanzen und Pflanzenteile behandelt werden. Unter Pflanzen werden hierbei alle Pflanzen und Pflanzenpopulationen verstanden, wie erwünschte und unerwünschte Wildpflanzen oder Kulturpflanzen (einschließlich natürlich vorkommender Kulturpflanzen). Kulturpflanzen können Pflanzen sein, die durch konventionelle Züchtungs- und Optimierungsmethoden oder durch biotechnologische und gentechnologische Methoden oder Kombinationen dieser Methoden erhalten werden können, einschließlich der transgenen Pflanzen und einschließlich der durch Sortenschutzr echte schützbaren oder nicht schützbaren Pflanzensorten. In the field of agriculture and in the forests, all plants and plant parts can be treated within the scope of the use of the co-crystals according to the invention. In this context, plants are understood as meaning all plants and plant populations, such as desired and undesired wild plants or crop plants (including naturally occurring crop plants). Crop plants can be plants that can be obtained by conventional breeding and optimization methods or by biotechnological and genetic engineering methods or combinations of these methods, including the transgenic plants and including the plant protectable or non-protectable plant varieties.
Unter Pflanzenteilen sollen alle oberirdischen und unterirdischen Teile und Organe der Pflanzen, wie Spross, Blatt, Blüte und Wurzel verstanden werden, wobei beispielhaft Blätter, Nadeln, Stängel, Stämme, Blüten, Fruchtkörper, Früchte und Saatgut sowie Wurzeln, Knollen und Rhizome aufgeführt werden. Zu den Pflanzenteilen gehört auch Erntegut sowie vegetatives und generatives Vermehrungsmaterial, beispielsweise Stecklinge, Knollen, Rhizome, Ableger und Saatgut.  Plant parts are to be understood as meaning all aboveground and underground parts and organs of the plants, such as shoot, leaf, flower and root, examples of which include leaves, needles, stems, stems, flowers, fruiting bodies, fruits and seeds, as well as roots, tubers and rhizomes. The plant parts also include crops and vegetative and generative propagation material, such as cuttings, tubers, rhizomes, offshoots and seeds.
Die erfindungsgemäße Behandlung der Pflanzen und Pflanzenteile mit den erfindungsgemäßen Co- Kristallen erfolgt direkt oder durch Einwirkung auf deren Umgebung, Lebensraum oder Lagerraum nach den üblichen Behandlungsmethoden, z.B. durch Tauchen, Sprühen, Verdampfen, Vernebeln, Streuen, Aufstreichen, Injizieren und bei Vermehrungsmaterial, insbesondere bei Saatgut, weiterhin durch ein- oder mehrschichtiges Umhüllen.  The treatment according to the invention of the plants and plant parts with the co-crystals according to the invention is carried out directly or by acting on their environment, habitat or storage space according to the usual treatment methods, e.g. by dipping, spraying, evaporating, atomizing, spreading, brushing, injecting and in propagating material, in particular in seeds, further by single or multilayer coating.
Als Pflanzen, welche im Rahmen der vorgenannten Verwendung der erfindungsgemäßen Co-Kristalle behandelt werden können, seien folgende erwähnt: Baumwolle, Flachs, Weinrebe, Obst, Gemüse, wie Rosaceae sp. (beispielsweise Kernfrüchte wie Apfel und Birne, aber auch Steinfrüchte wie Aprikosen, Kirschen, Mandeln und Pfirsiche und Beerenfrüchte wie Erdbeeren), Ribesioidae sp., Juglandaceae sp., Betulaceae sp., Anacardiaceae sp., Fagaceae sp., Moraceae sp., Oleaceae sp., Actinidaceae sp., Lauraceae sp., Musaceae sp. (beispielsweise Bananenbäume und -plantagen), Rubiaceae sp. (beispielsweise Kaffee), Theaceae sp., Sterculiceae sp., Rutaceae sp. (beispielsweise Zitronen, Organen und Grapefruit); Solanaceae sp. (beispielsweise Tomaten), Liliaceae sp., Asteraceae sp. (beispielsweise Salat), Umbelliferae sp., Cruciferae sp., Chenopodiaceae sp., Cucurbita-ceae sp. (beispielsweise Gurke), Alliaceae sp. (beispielsweise Lauch, Zwiebel), Papilionaceae sp. (beispielsweise Erbsen); Hauptnutzpflanzen, wie Gramineae sp. (beispielsweise Mais, Rasen, Getreide wie Weizen, Roggen, Reis, Gerste, Hafer, Hirse und Triticale), Asteraceae sp. (beispielsweise Sonnenblume), Brassicaceae sp. (beispielsweise Weißkohl, Rotkohl, Brokkoli, Blumenkohl, Rosenkohl, Pak Choi, Kohlrabi, Radieschen sowie Raps, Senf, Meerrettich und Kresse), Fabacae sp. (beispielsweise Bohnen, Erdnüsse), Papilionaceae sp. (beispielsweise Sojabohnen), Solanaceae sp. (beispielsweise Kartoffeln), Chenopodiaceae sp. (beispielsweise Zuckerrübe, Futterrübe, Mangold, Rote Rübe); Nutzpflanzen und Zierpflanzen in Garten und Wald; sowie jeweils genetisch modifizierte Arten dieser Pflanzen. Ein weiterer Gegenstand der vorliegenden Erfindung sind ferner Mittel zur Bekämpfung von tierischen Schädlingen, insbesondere von Insekten, Spinnentieren und/oder Nematoden, die in der Landwirtschaft, in den Forsten, im Vorrats- und Materialschutz sowie auf dem Hygienesektor vorkommen, welche die erfindungsgemäßen Co-Kristalle umfassen. As plants which can be treated in the context of the above-mentioned use of the co-crystals according to the invention, the following may be mentioned: cotton, flax, grapevine, fruits, vegetables, such as Rosaceae sp. (for example, pome fruits such as apple and pear, but also drupes such as apricots, cherries, almonds and peaches and soft fruits such as strawberries), Ribesioidae sp., Juglandaceae sp., Betulaceae sp., Anacardiaceae sp., Fagaceae sp., Moraceae sp., Oleaceae sp., Actinidaceae sp., Lauraceae sp., Musaceae sp. (for example, banana trees and plantations), Rubiaceae sp. (for example, coffee), Theaceae sp., Sterculiceae sp., Rutaceae sp. (for example, lemons, organs and grapefruit); Solanaceae sp. (for example tomatoes), Liliaceae sp., Asteraceae sp. (for example, lettuce), Umbelliferae sp., Cruciferae sp., Chenopodiaceae sp., Cucurbita ceae sp. (for example cucumber), Alliaceae sp. leek, onion), Papilionaceae sp. (for example, peas); Main crops, such as Gramineae sp. (for example corn, turf, cereals such as wheat, rye, rice, barley, oats, millet and triticale), Asteraceae sp. (for example sunflower), Brassicaceae sp. (for example, white cabbage, red cabbage, broccoli, cauliflower, Brussels sprouts, pak choi, kohlrabi, radishes and rapeseed, mustard, horseradish and cress), Fabacae sp. (for example, beans, peanuts), Papilionaceae sp. (for example, soybeans), Solanaceae sp. (for example potatoes), Chenopodiaceae sp. (for example, sugar beet, fodder beet, Swiss chard, beet); Useful plants and ornamental plants in the garden and forest; and each genetically modified species of these plants. The present invention further provides compositions for controlling animal pests, in particular insects, arachnids and / or nematodes, which are found in agriculture, in forestry, in the protection of stored products and in the hygiene sector, and which comprise the co-product of the invention. Include crystals.
Aufgrund ihrer Stabilität eignen sich die erfindungsgemäßen Co-Kristalle ganz allgemein als Ausgangsmaterial für die Herstellung jedweder die Verbindung 4-{[(6-Chlorpyrid-3-yl)methyl](2,2- difluorethyl)amino}furan-2(5H)-on enthaltender formulierter Mittel zur Bekämpfung von S c h ä d l i n g e n , a u c h w e n n d i e V e r b i n d u n g 4-{[(6-Chlorpyrid-3-yl)methyl](2,2- difluorethyl)amino}furan-2(5H)-on nach der Formulierung nicht mehr als Co-Kristall, sondern etwa in gelöster Form vorliegt. Because of their stability, the co-crystals of the present invention are generally useful as starting materials for the preparation of any of the compounds 4 - {[(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino} furan-2 (5H) formulated agent for control of chicks, even when the compound is 4 - {[(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino} furan-2 (5H) -one according to the Formulation is no longer present as a co-crystal, but rather in dissolved form.
Insbesondere eignen sich die erfindungsgemäßen Co-Kristalle zur Herstellung von Mitteln zur Behandlung von Saatgut.  In particular, the co-crystals according to the invention are suitable for the production of compositions for the treatment of seed.
So entsteht ein großer Teil des durch Schädlinge verursachten Schadens an Kulturpflanzen bereits durch den Befall des Saatguts während der Lagerung und nach dem Einbringen des Saatguts in den Boden sowie während und unmittelbar nach der Keimung der Pflanzen. Diese Phase ist besonders kritisch, da die Wurzeln und Sprosse der wachsenden Pflanze besonders empfindlich sind und bereits ein geringer Schaden zum Absterben der ganzen Pflanze führen kann. Es besteht daher ein insbesondere großes Interesse daran, das Saatgut und die keimende Pflanze durch den Einsatz geeigneter Mittel zu schützen.  Thus, a large part of the damage caused by pests crops already by the infestation of the seed during storage and after the introduction of the seed into the soil and during and immediately after the germination of the plants. This phase is particularly critical, as the roots and shoots of the growing plant are particularly sensitive and even minor damage can lead to the death of the entire plant. There is therefore a particular interest in protecting the seed and the germinating plant by the use of suitable agents.
Die vorliegende Erfindung bezieht sich daher insbesondere auch auf ein Verfahren zum Schutz von Saatgut, insbesondere transgenem Saatgut, und keimenden Pflanzen vor dem Befall von Schädlingen, in dem das Saatgut mit einem der erfindungsgemäßen Mittel behandelt wird. The present invention therefore also relates, in particular, to a method for the protection of seeds, in particular transgenic seed, and germinating plants from the infestation of pests, in which the seed is treated with one of the agents according to the invention.
Die Erfindung bezieht sich ebenfalls auf die Verwendung der erfindungsgemäßen Mittel zur Behandlung von Saatgut zum Schutz des Saatguts und der daraus entstehenden Pflanze vor Schädlingen. Weiterhin bezieht sich die Erfindung auf Saatgut, welches zum Schutz vor Schädlingen mit einem erfindungsgemäßen Mittel behandelt wurde.  The invention also relates to the use of the agents according to the invention for the treatment of seeds for the protection of the seed and the resulting plant from pests. Furthermore, the invention relates to seed which has been treated with an agent according to the invention for protection against pests.
Wie vorstehend bereits erwähnt, kommt auch der Behandlung von transgenem Saatgut mit einem erfindungsgemäßen Mittel eine besondere Bedeutung zu. Dabei handelt es sich um das Saatgut von Pflanzen, die in der Regel zumindest ein heterologes Gen enthalten, das die Expression eines Polypeptids mit insbesondere msektiziden Eigenschaften steuert. Die heterologen Gene in transgenem Saatgut können dabei aus Mikroorganismen wie Bacillus, Rhizobium, Pseudomonas, Serratia, Tri- choderma, Clavibacter, Glomus oder Gliocladium stammen.  As already mentioned above, the treatment of transgenic seed with an agent according to the invention is of particular importance. These are the seeds of plants, which as a rule contain at least one heterologous gene which controls the expression of a polypeptide having in particular insecticidal properties. The heterologous genes in transgenic seed can come from microorganisms such as Bacillus, Rhizobium, Pseudomonas, Serratia, Trichoderma, Clavibacter, Glomus or Gliocladium.
Die vorliegende Erfindung eignet sich besonders für die Behandlung von transgenem Saatgut, das zumindest ein heterologes Gen enthält, das aus Bacillus sp. stammt und dessen Genprodukt Wirksamkeit gegen Maiszünsler und/oder Maiswurzel-Bohrer zeigt. Besonders bevorzugt handelt es sich dabei um ein heterologes Gen, das aus Bacillus thuringiensis stammt. The present invention is particularly useful for the treatment of transgenic seed containing at least one heterologous gene derived from Bacillus sp. and its gene product Efficacy against European corn borer and / or corn rootworm shows. Most preferably, this is a heterologous gene derived from Bacillus thuringiensis.
Einer der Vorteile der vorliegenden Erfindung ist es, dass aufgrund der besonderen systemischen Eigenschaft des in den erfindungsgemäßen C o-Kristallen enthaltenen 4-{[(6-Chlorpyrid-3- yl)methyl](2,2-difluorethyl)amino}furan-2(5H)-on di e B ehandlung de s S aatguts mit den erfindungsgemäßen Mitteln nicht nur das Saatgut selbst, sondern auch die daraus hervorgehende Pflanze nach dem Auflaufen, vor Schädlingen schützt. One of the advantages of the present invention is that, owing to the particular systemic property of the 4 - {[(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino} fluorine contained in the C o crystals according to the invention, 2 (5H) -one of the treatment of the seed with the agents according to the invention not only protects the seed itself, but also the resulting plant after emergence, from pests.
Die Erfindung schließt auch Zusammensetzungen ein, die die erfindungsgemäßen Co-Kristalle enthalten. Bevorzugt sind Zusammensetzungen, die weniger als 20 Gew.-% der erfindungsgemäßen Co-Kristalle, besonders bevorzugt weniger als 15 Gew.-%, ganz besonders bevorzugt mit weniger als 10 Gew.-%, insbesondere bevorzugt mit weniger als 5 Gew. %, am meisten bevorzugt mit weniger als 4, 3, 2 oder 1 Gew.-% der erfindungsgemäßen Co-Kristalle in der Zusammensetzung enthalten. Erfindungsgemäß umfassen Zusammensetzungen auch die vorgenannten Mittel.  The invention also includes compositions containing the co-crystals of the invention. Preference is given to compositions which contain less than 20% by weight of the co-crystals according to the invention, more preferably less than 15% by weight, very particularly preferably less than 10% by weight, particularly preferably less than 5% by weight, most preferably containing less than 4, 3, 2 or 1% by weight of the co-crystals of the invention in the composition. According to the invention, compositions also comprise the aforementioned agents.
Die erfindungsgemäßen Co-Kristalle können in bekannter Weise in die üblichen Formulierungen überführt werden, wie Suspensionskonzentrate, Öl basierte Suspensionskonzentrate, kolloidale Konzentrate, Dispergierbare Konzentrate, Emulgierbare Konzentrate (Emulsionskonzentrate), Emulsionsbeizen, Suspensionsbeizen, Granulate, Mikrogranulate, Suspoemulsionen, wasserlösliche Granulate, wasserlösliche Konzentrate und wasserdispergierbare Granulate, unter Verwendung geeigneter Hilfs- und Trägerstoffe oder Lösemittel. The co-crystals according to the invention can be converted into the customary formulations in a known manner, such as suspension concentrates, oil-based suspension concentrates, colloidal concentrates, dispersible concentrates, emulsifiable concentrates (emulsion concentrates), emulsion mordants, suspension mordants, granules, microgranules, suspoemulsions, water-soluble granules, water-soluble concentrates and water-dispersible granules, using suitable auxiliaries and carriers or solvents.
Hierbei soll die wirksame Verbindung 4-{[(6-Chlorpyrid-3-yl)methyl](2,2-difluorethyl)amino}furan- 2(5H)-on in einer Konzentration von etwa 0,5 bis 90 Gew.-% der Zusammensetzung enthaltend die erfindungsgemäßen Co-Kristalle vorhanden sein, d.h. in Mengen, die ausreichend sind, um den notwendigen Dosierungsspiegel zu erreichen.  Here, the active compound 4 - {[(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino} furan-2 (5H) -one in a concentration of about 0.5 to 90 wt. % of the composition containing the co-crystals according to the invention, ie in amounts sufficient to achieve the necessary dosage level.
Die Formulierungen werden beispielsweise hergestellt durch Verstrecken der erfindungsgemäßen Co- Kristalle mit Wasser, Lösemitteln und/oder Trägerstoffen, gegebenenfalls unter Verwendung von Emulgier- und/o der D isp ergi ermitte ln, und/o der anderen Hil fs sto ffen, wi e z . B . Penetrationshilfsmitteln. For example, the formulations are prepared by stretching the co-crystals of the invention with water, solvents and / or carriers, optionally using emulsifying and / or disperse powers, and / or the other adjuvants, e.g. B. Penetration aids.
Bei der Herstellung von Suspensionskonzentraten, auch von solchen, die zur Saatgutbehandlung verwendet werden, werden im Allgemeinen neben dem Wirkstoff und einem Streckmittel (Wasser, Lösungsmittel oder Öl) weitere Hilfsmittel zugegeben. Zur Befeuchtung des Wirkstoffs in der kontinuierlichen Phase wird ein Netzmittel eingesetzt, zur Stabilisierung der Suspension in der flüssigen Phase werden Dispergierhilfsmittel verwendet, zum Emulgieren der nicht wässerigen Phase werden bei Lösungsmittel oder Öl enthaltenden Suspensionskonzentraten Emulgiermittel eingesetzt. Sofern notwendig werden Frostschutzmittel, Biozide, Verdickungsmittel, Farbstoffe Spreizmittel oder/und Aufnahmeförderer eingearbeitet. In the preparation of suspension concentrates, including those used for seed treatment, further adjuvants are generally added in addition to the active ingredient and an extender (water, solvent or oil). For wetting the active ingredient in the continuous phase, a wetting agent is used to stabilize the suspension in the liquid phase dispersing agents are used for emulsifying the non-aqueous phase are used in solvent or oil-containing suspension concentrates emulsifiers. If necessary, anti-freeze agents, biocides, thickeners, dyes, spreading agents and / or absorption promoters are incorporated.
Die erfindungsgemäßen Co-Kristalle können weiterhin in andere übliche Formulierungen überführt werden, wie Lösungen, Emulsionen, Spritzpulver, wasser- und ölbasierte Suspensionen, Pulver, Stäubemittel, Pasten, lösliche Pulver, lösliche Granulate, Streugranulate, Suspensions-Emulsions- Konzentrate, Co-Kristall-imprägnierte Naturstoffe, Co-Kristall-imprägnierte synthetische Stoffe, Düngemittel sowie Feinstverkapselungen in polymeren Stoffen.  The co-crystals according to the invention can furthermore be converted into other customary formulations, such as solutions, emulsions, wettable powders, water- and oil-based suspensions, powders, dusts, pastes, soluble powders, soluble granules, scattering granules, suspension-emulsion concentrates, co-crystal impregnated natural products, co-crystal-impregnated synthetic materials, fertilizers and Feinstverkapselungen in polymeric materials.
Diese Formulierungen werden in bekannter Weise hergestellt, z.B. durch Vermischen der erfindungsgemäßen Co-Kristalle mit Streckmitteln, also flüssigen Lösungsmitteln und/oder festen Trägerstoffen, gegebenenfalls unter Verwendung von oberflächenaktiven Mitteln, also Emulgiermitteln und/oder Dispergiermitteln und/oder schaumerzeugenden Mitteln. Die Herstellung der Formulierungen erfolgt entweder in geeigneten Anlagen oder auch vor oder während der Anwendung.  These formulations are prepared in a known manner, e.g. by mixing the co-crystals according to the invention with extenders, ie liquid solvents and / or solid carriers, if appropriate using surface-active agents, ie emulsifiers and / or dispersants and / or foam-forming agents. The preparation of the formulations is carried out either in suitable systems or before or during use.
Als Hilfsstoffe können solche Stoffe Verwendung finden, die geeignet sind, dem Mittel selbst oder und/oder davon abgeleitete Zubereitungen (z.B. Spritzbrühen, Saatgutbeizen) besondere Eigenschaften zu verleihen, wie bestimmte technische Eigenschaften und/oder auch besondere biologische Eigenschaften. Als typische Hilfsmittel kommen in Frage: Streckmittel, Lösemittel und Trägerstoffe. Excipients which can be used are those which are suitable for imparting special properties to the composition itself and / or preparations derived therefrom (for example spray liquor, seed dressing), such as certain technical properties and / or specific biological properties. Typical auxiliaries are: extenders, solvents and carriers.
Als Streckmittel eignen sich z.B. Wasser, polare und unpolare organische chemische Flüssigkeiten z.B. aus den Klassen der aromatischen und nicht-aromatischen Kohlenwasserstoffe (wie Paraffine, Alkylbenzole, Alkylnaphthaline, Chlorbenzole), der Alkohole und Polyole (die ggf. auch substituiert, verethert und/oder verestert sein können), der Ketone (wie Aceton, Cyclohexanon), Ester (auch Fette und Öle) und (poly-)Ether, der einfachen und substituierten Amine, Amide, Lactame (wie N- Alkylpyrrolidone) und Lactone, der Sulfone und Sulfoxide (wie Dimethylsulfoxid). As extender, e.g. Water, polar and non-polar organic chemical liquids e.g. from the classes of aromatic and non-aromatic hydrocarbons (such as paraffins, alkylbenzenes, alkylnaphthalenes, chlorobenzenes), alcohols and polyols (which may also be substituted, etherified and / or esterified), ketones (such as acetone, cyclohexanone), Esters (including fats and oils) and (poly) ethers, simple and substituted amines, amides, lactams (such as N-alkylpyrrolidones) and lactones, sulfones and sulfoxides (such as dimethylsulfoxide).
Im Falle der Benutzung von Wasser als Streckmittel können z.B. auch organische Lösemittel als Hilfslösungsmittel verwendet werden. Als flüssige Lösemittel kommen im wesentlichen in Frage: Aromaten, wie Xylol, Toluol, oder Alkylnaphthaline, chlorierte Aromaten und chlorierte aliphatische Kohlenwasserstoffe, wie Chlorbenzole, Chlorethylene oder Methylenchlorid, aliphatische Kohlenwasserstoffe, wie Cyclohexan oder Paraffine, z.B. Erdölfraktionen, mineralische und pflanzliche Öle, Alkohole, wie Butanol oder Glykol sowie deren Ether und Ester, Ketone wie Aceton, Methylethylketon, Methylisobutylketon oder Cyclohexanon, stark polare Lösungsmittel, wie Dimethylsulfoxid, sowie Wasser.  In the case of using water as an extender, e.g. also organic solvents can be used as auxiliary solvent. Suitable liquid solvents are essentially: aromatics, such as xylene, toluene, or alkylnaphthalenes, chlorinated aromatics and chlorinated aliphatic hydrocarbons, such as chlorobenzenes, chloroethylenes or methylene chloride, aliphatic hydrocarbons, such as cyclohexane or paraffins, e.g. Petroleum fractions, mineral and vegetable oils, alcohols such as butanol or glycol and their ethers and esters, ketones such as acetone, methyl ethyl ketone, methyl isobutyl ketone or cyclohexanone, strongly polar solvents such as dimethyl sulfoxide, and water.
Erfindungsgemäß bedeutet Trägerstoff eine natürliche oder synthetische, organische oder anorganische Substanz, welcher fest oder flüssig sein kann, mit welchen die Wirkstoffe zur besseren Anwendbarkeit, insbesondere zum Aufbringen auf Pflanzen oder Pflanzenteile oder Saatgut, gemischt oder verbunden sind. Der feste oder flüssige Trägerstoff ist im Allgemeinen inert und sollte in der Landwirtschaft verwendbar sein. According to the invention, the carrier means a natural or synthetic, organic or inorganic substance, which may be solid or liquid, with which the active ingredients for better applicability, in particular for application to plants or plant parts or seeds mixed or are connected. The solid or liquid carrier is generally inert and should be useful in agriculture.
Als feste oder flüssige Trägerstoffe kommen z.B. Ammoniumsalze und natürliche Gesteinsmehle, wie Kaoline, Tonerden, Talkum, Kreide, Quarz, Attapulgit, Montmorillonit oder Diatomeenerde und synthetische Gesteinsmehle, wie hochdisperse Kieselsäure, Aluminiumoxid und Silikate in Frage. Als feste Trägerstoffe für Granulate kommen insbesondere z.B. gebrochene und fraktionierte natürliche Gesteine wie Calcit, Marmor, Bims, Sepiolith, Dolomit sowie synthetische Granulate aus anorganischen und organischen Mehlen sowie Granulate aus organischem Material wie Papier, Sägemehl, Kokosnussschalen, Maiskolben und Tabakstängeln in Frage.  Solid or liquid carriers are e.g. Ammonium salts and ground natural minerals, such as kaolins, clays, talc, chalk, quartz, attapulgite, montmorillonite or diatomaceous earth and synthetic minerals, such as finely divided silica, alumina and silicates in question. As solid carriers for granules, in particular e.g. Cracked and fractionated natural rocks such as calcite, marble, pumice, sepiolite, dolomite and synthetic granules of inorganic and organic flours and granules of organic material such as paper, sawdust, coconut shells, corncobs and tobacco stems in question.
Als Emulgier- und/oder schaumerzeugende Mittel kommen z.B. nicht-ionogene und anionische Emulgatoren, wie Polyoxyethylen-Fettsäure-Ester, Polyoxyethylen-Fettalkohol-Ether, wie z.B. Alkylarylpolyglykolether, Alkylsulfonate, Alkylsulfate, Arylsulfonate sowie Eiweißhydrolysate in Frage. As emulsifying and / or foaming agents there are e.g. non-ionic and anionic emulsifiers, such as polyoxyethylene fatty acid esters, polyoxyethylene fatty alcohol ethers, e.g. Alkylarylpolyglykolether, alkylsulfonates, alkyl sulfates, arylsulfonates and protein hydrolysates in question.
Als Dispergiermittel kommen nicht-ionische und/oder ionische Stoffe, z.B. aus den Klassen der Alkohol-POE- und/oder POP-Ether, Säure- und/oder POP- POE-Ester, Alkyl-Aryl- und/oder POP- POE-Ether, Fett- und/oder POP- POE-Addukte, POE- und/oder POP-Polyol Derivate, POE- und/oder POP-Sorbitan- oder Zucker- Addukte, Alky- oder Aryl-Sulfate, Sulfonate und Phosphate oder die entsprechenden PO-Ether- Addukte in Frage.  Dispersants used are nonionic and / or ionic substances, e.g. from the classes of alcohol POE and / or POP ethers, acid and / or POP POE esters, alkyl aryl and / or POP POE ethers, fatty and / or POP POE adducts, POE and / or POP polyol derivatives, POE and / or POP sorbitol or sugar adducts, alkyl or aryl sulfates, sulfonates and phosphates or the corresponding PO ether adducts in question.
Ferner geeignete Oligo- oder Polymere, sind z.B. jene ausgehend von vinylischen Monomeren, von Acrylsäure, aus EO und/oder PO allein oder in Verbindung mit z.B. (poly-) Alkoholen oder (poly-) Aminen. Ferner können Lignin und seine Sulfonsäure-Derivate, einfache und modifizierte Cellulosen, aromatische und/oder aliphatische Sulfonsäuren sowie deren Addukte mit Formaldehyd Einsatz finden.  Further suitable oligo- or polymers are e.g. those starting from vinylic monomers, from acrylic acid, from EO and / or PO alone or in combination with e.g. (poly) alcohols or (poly) amines. Furthermore, lignin and its sulfonic acid derivatives, simple and modified celluloses, aromatic and / or aliphatic sulfonic acids and their adducts with formaldehyde can be used.
Es können in den Formulierungen Haftmittel wie Carboxymethylcellulose, natürliche und synthetische pulvrige, körnige oder latexförmige Polymere verwendet werden, wie Gummiarabicum, Poly- vinylalkohol, Polyvinylacetat, sowie natürliche Phospholipide, wie Kephaline und Lecithine und synthetische Phospholipide.  Adhesives such as carboxymethylcellulose, natural and synthetic powdery, granular or latex-type polymers can be used in the formulations, such as gum arabic, polyvinyl alcohol, polyvinyl acetate, as well as natural phospholipids such as cephalins and lecithins and synthetic phospholipids.
Es können Farbstoffe wie anorganische Pigmente, z.B. Eisenoxid, Titanoxid, Ferrocyanblau und organische Farbstoffe, wie Alizarin-, Azo- und Metallphthalocyaninfarbstoffe und Spurennährstoffe wie Salze von Eisen, Mangan, Bor, Kupfer, Kobalt, Molybdän und Zink verwendet werden.  Dyes such as inorganic pigments, e.g. Iron oxide, titanium oxide, ferrocyan blue and organic dyes such as alizarin, azo and metal phthalocyanine dyes and trace nutrients such as salts of iron, manganese, boron, copper, cobalt, molybdenum and zinc.
Weitere Additive können Duftstoffe, mineralische oder vegetabile gegebenenfalls modifizierte Öle, Wachse und Nährstoffe (auch Spurennährstoffe), wie Salze von Eisen, Mangan, Bor, Kupfer, Kobalt, Molybdän und Zink sein. Weiterhin enthalten sein können Stabilisatoren wie Kältestabilisatoren, Konservierungsmittel, Oxidationsschutzmittel, Lichtschutzmittel oder andere die chemische und/oder physikalische Stabilität verbessernde Mittel. Other additives may be fragrances, mineral or vegetable optionally modified oils, waxes and nutrients (also trace nutrients), such as salts of iron, manganese, boron, copper, cobalt, molybdenum and zinc. Stabilizers such as cold stabilizers, preservatives, antioxidants, light stabilizers or other chemical and / or physical stability-improving agents may also be present.
Der Gehalt von 4-{[(6-Chlo^yrid-3-yl)methyl](2,2-difluorethyl)amino}furan-2(5H)-on der aus den Formulierungen bereiteten Anwendungsformen kann in weiten Bereichen variieren. Der Gehalt von 4- {[(6-Chlo^yrid-3-yl)methyl](2,2-difluorethyl)amino}furan-2(5H)-on der Anwendungsformen liegt im Bereich von 0,00000001 bis 97 Gew.-%, vorzugsweise im Bereich von 0,0000001 bis 97 Gew.-%, besonders bevorzugt im Bereich von 0,000001 bis 83 Gew.-% oder 0,000001 bis 5 Gew.-% und ganz besonders bevorzugt im Bereich von 0,0001 bis 1 Gew.-%.  The content of 4 - {[(6-chloro-3-yl) methyl] (2,2-difluoroethyl) amino} furan-2 (5H) -one of the use forms prepared from the formulations can vary widely. The content of 4- {[(6-chloro-3-yl) methyl] (2,2-difluoroethyl) amino} furan-2 (5H) -one of the use forms is in the range of 0.00000001 to 97 wt. %, preferably in the range of 0.0000001 to 97% by weight, more preferably in the range of 0.000001 to 83% by weight or 0.000001 to 5% by weight and most preferably in the range of 0, 0001 to 1 wt .-%.
Die erfindungsgemäßen Co-Kristalle können gegebenenfalls in bestimmten Konzentrationen bzw. Aufwandmengen zusammen mit Herbiziden, Safenern, Wachstumsregulatoren oder Mitteln zur Verbesserung der Pflanzeneigenschaften, oder mit Mikrobiziden, b e ispielsweise Fungiziden, insbesondere Antimykotika, Bakteriziden, Viriziden (einschließlich Mittel gegen Viroide) oder mit Mitteln gegen MLO (Mycoplasma-like-organism) und RLO (Rickettsia-like-organism) verwendet werden. The co-crystals according to the invention may optionally be used in certain concentrations or application rates together with herbicides, safeners, growth regulators or agents for improving plant properties, or with microbicides, be fungsweise fungicides, in particular antimycotics, bactericides, viricides (including anti-viral agents) or agents against MLO (Mycoplasma-like-organism) and RLO (Rickettsia-like-organism).
Die Erfindung wird nachfolgend anhand von Beispielen und Abbildungen näher erläutert, ohne sie jedoch hierdurch darauf zu beschränken.  The invention will be explained in more detail below with reference to examples and figures, without, however, restricting them thereto.
Den nachfolgenden Abbildungen Fig. 1 und Fig. 2 gemein ist, dass in diesen jeweils die gemäß der Ausführungsbeispiele ermittelten Intensitäten einer Röntgenstrahlung [I] über dem Doppelten des jeweils bemessenen Beugungswinkels [2 Θ] dargestellt ist.  Common to FIGS. 1 and 2 below is that these show in each case the intensities of an X-ray radiation [I] determined in accordance with the exemplary embodiments over twice the respectively dimensioned diffraction angle [2 Θ].
Fig. 1 zeigt eine Röntgenbeugungsanalyse eines Pulvers des erfindungsgemäßen Co-Kristalls enthaltend 4-{[(6-Chlorpyrid-3-yl)methyl](2,2-difluorethyl)amino} furan-2(5H)-on und Salizylsäure als Co-Former gemäß dem Beispiel 2 in Verbindung mit Beispiel 4.  Fig. 1 shows an X-ray diffraction analysis of a powder of the co-crystal of the present invention containing 4 - {[(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino} furan-2 (5H) -one and salicylic acid as Co -Former according to Example 2 in conjunction with Example 4.
Fig. 2 zeigt eine Röntgenbeugungsanalyse eines Pulvers des erfindungsgemäßen Co-Kristalls enthaltend 4-{[(6-Chlorpyrid-3-yl)methyl](2,2-difluorethyl)amino}furan-2(5H)-on und als Salizylsäure Co-Former gemäß dem Beispiel 3 in Verbindung mit Beispiel 4.  Fig. 2 shows an X-ray diffraction analysis of a powder of the co-crystal of the present invention containing 4 - {[(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino} furan-2 (5H) -one and as salicylic acid Co -Former according to Example 3 in conjunction with Example 4.
Fig. 3 zeigt Messdaten einer differentielle Kalorimetrie (DSC) gemäß dem Beispiel 5, aufgetragen als bei einer Temperatur (T) aufgenommene Wärmeleistung (P) eines Pulvers von 4-{[(6-Chlorpyrid-3- yl)methyl](2,2-difluorethyl)amino} furan-2(5H)-on gemäß Beispiel 1 (A) und eines Pulvers aus Beispiel 2 (B). Beispiele: 3 shows measured data of a differential calorimetry (DSC) according to example 5, plotted as thermal power (P) of a powder of 4 - {[(6-chloropyrid-3-yl) methyl] taken up at a temperature (T) (FIG. 2-difluoroethyl) amino} furan-2 (5H) -one according to Example 1 (A) and a powder from Example 2 (B). Examples:
Beispiel 1: Herstellen von 4-{[(6-Chlorpyrid-3-yl)methyl](2,2-difluorethyl)amino}furan-2(5H)-on Example 1: Preparation of 4 - {[(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino} furan-2 (5H) -one
4-{[(6-Chlo^yrid-3-yl)methyl](2,2-difluorethyl)amino}furan-2(5H)-on wurde gemäß dem Beispiel 2 der WO 2009/036899 AI hergestellt und in den Beispielen 2 und 3 zur Herstellung der erfindungsgemäßen Co-Kristalle verwendet. 4 - {[(6-Chloro-3-yl) -methyl] (2,2-difluoroethyl) -amino} -furan-2 (5H) -one was prepared according to Example 2 of WO 2009/036899 A1 and in the examples 2 and 3 used to prepare the co-crystals of the invention.
Beispiel 2: Herstellen eines Co-Kristall-Pulvers  Example 2: Preparation of a co-crystal powder
163 mg 4-{[(6-Chlo^yrid-3-yl)methyl](2,2-difluorethyl)amino}furan-2(5H)-on aus Beispiel 1 wurden mit 77 mg Salizylsäure in einem 2 ml Reaktionsgefäß (Fa. Eppendorf) vermischt. Der Mischung wurden 30 μΐ flüssiges Ethylacetat zugegeben. Der somit erhaltene Inhalt des vorgenannten Reaktionsgefäßes wurde zusammen mit 7 Edelstahlkugeln eines Durchmessers von 3 mm in eine Retsch MM200 Schwingmühle überführt und in dieser für 60 Minuten bei 30 Hz gemahlen.  163 mg of 4 - {[(6-chloro-3-yl-3-yl) methyl] (2,2-difluoroethyl) amino} furan-2 (5H) -one from Example 1 were mixed with 77 mg of salicylic acid in a 2 ml reaction vessel ( From Eppendorf). To the mixture was added 30 μL of liquid ethyl acetate. The thus obtained contents of the aforementioned reaction vessel was transferred together with 7 stainless steel balls of a diameter of 3 mm in a Retsch MM200 vibration mill and milled in this for 60 minutes at 30 Hz.
Das gemahlene Gut wurde über Nacht bei Raumtemperatur (23°C) und Umgebungsdruck (1013 hPa) getrocknet, um das Ethylacetat zu verdunsten. Es wurde ein Pulver erhalten, das dem Beispiel 4 und 5 zugeführt wurde.  The milled material was dried overnight at room temperature (23 ° C) and ambient pressure (1013 hPa) to evaporate the ethyl acetate. A powder was obtained which was supplied to Examples 4 and 5.
Beispiel 3: Herstellen eines Einkristalls des Co-Kristalls Example 3: Preparation of a single crystal of the co-crystal
2 ml einer gesättigten Lösung von 4-{[(6-Chlorpyrid-3-yl)methyl](2,2-difluorethyl)amino}furan- 2(5H)-on aus Beispiel 1 in Ethylacetat wurden mit 2 ml gesättigter Salizylsäure-Lösung in Ethylacetat versetzt und durch schütteln vermischt.  2 ml of a saturated solution of 4 - {[(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino} furan-2 (5H) -one from Example 1 in ethyl acetate was mixed with 2 ml of saturated salicylic acid. Solution in ethyl acetate and mixed by shaking.
Über Nacht bildeten sich bei Raumtemperatur (23°C) und unter Umgebungsdruck (1013 hPa) Kristalle von ca. 1 mm Größe.  Crystals of about 1 mm size were formed overnight at room temperature (23 ° C.) and under ambient pressure (1013 hPa).
Einzelne Einkristalle werden entnommen und dem Versuch gemäß dem Beispiel 6 zugeführt. Die verbleibenden Kristalle werden mit Hand zermörsert und einer Untersuchung gemäß dem Beispiel 4 zugeführt.  Individual single crystals are removed and fed to the experiment according to Example 6. The remaining crystals are crushed by hand and subjected to a study according to Example 4.
Beispiel 4: Pulver-Röntgendiffraktometrische Messung (p-XRD) des Pulvers aus den Beispielen 2 und 3  Example 4: Powder X-ray diffractometric measurement (p-XRD) of the powder from Examples 2 and 3
Das aus den Beispielen 2 und 3 erhaltene Pulver wurde mit einem Röntgendiffraktometer (Fa. Stoe, Typ. STADI-P Transmissionsdiffraktometer, Primärmonochromator: Ge[l 1 1], Strahlungsquelle; CUKOLI, Wellenlänge 1.54 Ä, Detektor: Linearer PSD) untersucht. Die Untersuchung des Pulvers aus dem Beispiel 2 ergab das in Fig. 1 dargestellte charakteristische Röntgendiffraktogramm. Die Untersuchung des Pulvers aus dem Beispiel 3 ergab das in Fig. 2 dargestellte charakteristische Röntgendiffraktogramm. The powder obtained from Examples 2 and 3 was examined by means of an X-ray diffractometer (Stoe, type STADI-P transmission diffractometer, primary monochromator: Ge [11], radiation source, CU KOL I, wavelength 1.54 λ, detector: linear PSD) , Examination of the powder of Example 2 yielded the characteristic X-ray diffractogram shown in FIG. Examination of the powder of Example 3 yielded the characteristic X-ray diffractogram shown in FIG.
Man erkennt, dass die Fig. 1 und Fig. 2 Röntgendiffraktogramme des gleichen Stoffes sind. Beide Röntgendiffraktogramme sind von j enen der Reinstoffe 4-{[(6-Chlorpyrid-3-yl)methyl](2,2- difluorethyl)amino}furan-2(5H)-on und Salizylsäure verschieden (beide hier nicht dargestellt). Demnach bilden beide erfindungsgemäßen Verfahren zur Herstellung eines erfindungsgemäßen Co- Kristalls den gleichen Co-Kristall. It can be seen that FIGS. 1 and 2 are X-ray diffractograms of the same substance. Both X-ray diffractograms are of one of the pure substances 4 - {[(6-chloropyrid-3-yl) methyl] (2,2-) difluoroethyl) amino} furan-2 (5H) -one and salicylic acid (both not shown here). Accordingly, both inventive methods for producing a Co crystal according to the invention form the same co-crystal.
Beispiel 5: Differentielle Kalorimetrie (DSC) der Pulver aus dem Beispiel 2, sowie von 4-{[(6- Chlorpyrid-3-yl)methyl](2,2-difluorethyl)amino}furan-2(5H)-on aus dem Beispiel 1  Example 5: Differential calorimetry (DSC) of the powders of Example 2 and of 4 - {[(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino} furan-2 (5H) -one Example 1
Das aus den Beispiel 2 erhaltene Pulver, sowie Pulver von 4-{[(6-Chlorpyrid-3-yl)methyl](2,2- difluorethyl)amino}furan-2(5H)-on werden in einem differentiellen Kalorimeter (Fa. Mettler-Toledo, Typ: DSC 822) untersucht. Die Ergebnisse der Messungen sind in der Fig. 3 dargestellt.  The powder obtained from Example 2, and powder of 4 - {[(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino} furan-2 (5H) -one are in a differential calorimeter (Fa Mettler-Toledo, type: DSC 822). The results of the measurements are shown in FIG.
Man erkennt für jedes der untersuchten Pulver nur jeweils einen Schmelzpunkt, was im Fall des Pulvers von 4- {[(6-Chlorpyrid-3-yl)methyl](2,2-difluorethyl)amino} furan-2(5H)-on der Schmelzpunkt von etwa 72-74°C der Reinsubstanz ist, der in dem Pulver aus dem Beispiel 2 durch die Bildung des erfindungsgemäßen Co-Kristalls verändert ist.  Only one melting point is seen for each of the powders examined, which in the case of the powder of 4- {[(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino} furan-2 (5H) -one is the melting point of about 72-74 ° C of the pure substance, which is changed in the powder of Example 2 by the formation of the co-crystal according to the invention.
Die Feststellung, dass jeweils nur ein Schmelzpunkt ermittelt wurde zeigt, dass es sich bei dem Pulver aus dem Beispiel 2 nicht um ein Gemisch der jeweiligen Reinstoffe handelt.  The finding that only one melting point was determined shows that the powder from Example 2 is not a mixture of the respective pure substances.
Der Schmelzpunkt des Co-Kristalls aus 4-{[(6-Chlorpyrid-3-yl)methyl](2,2-difluorethyl)amino}furan- 2(5H)-on und Salizylsäure gemäß dem Beispiel 2 beträgt etwa 85°C. The melting point of the co-crystal of 4 - {[(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino} furan-2 (5H) -one and salicylic acid according to Example 2 is about 85 ° C ,
Somit wird durch die Bildung der erfindungsgemäßen Co-Kristalle der Schmelzpunkt des resultierenden Stoffs erhöht.  Thus, by forming the co-crystals of the present invention, the melting point of the resulting substance is increased.
Beispiel 6: Röntgenbeugungsanalyse (XRD) des Einkristalls aus dem Beispiel 3  Example 6: X-ray diffraction analysis (XRD) of the single crystal from Example 3
Ein farbloser Kristall der ungefähren Abmaße 0,50 x 0,20 x 0,15 mm3 aus Beispiel 3 wurde in einem Diffraktometer (Fa. Oxford Diffraction, Typ: Xcalibur) ausgerüstet mit einem CCD Flächendetektor (Model: Ruby), einer CuKa Strahlungsquelle und einer Cryojet Niedrigtemperaturvorrichtung (T =100 K) untersucht. Die Messdaten wurden in alle Raumrichtungen aufgenommen, d.h. es wurde der Detektor um einen horizontalen und einen vertikalen Winkel vollständig um die Probe bewegt. A colorless crystal of the approximate dimensions 0.50 × 0.20 × 0.15 mm 3 from Example 3 was used in a diffractometer (Oxford Diffraction, type: Xcalibur) equipped with a CCD area detector (model: Ruby), a Cu Ka Radiation source and a cryojet low temperature device (T = 100 K) examined. The measured data were recorded in all spatial directions, ie the detector was moved completely around the sample by one horizontal and one vertical angle.
Die Messdaten wurden mittels der Software Crysalis (Fa. Oxford Diffraction 2007) gesammelt und protokolliert. The measurement data were collected and logged using the software Crysalis (Oxford Diffraction 2007).
Die Lösung der Kristallstrukturgleichungen wurde mittels direkter Methoden ausgeführt, wie sie in dem verwendeten Programm SHELXTL Version 6.10 (Sheldrick, Universtität Göttingen, Germany, 2000) implementiert sind.  The solution of the crystal structure equations was carried out by direct methods, as implemented in the program SHELXTL Version 6.10 (Sheldrick, University of Göttingen, Germany, 2000).
Hiernach wurden die Daten visualisiert, wonach ein stöchiometrisches Verhältnis von 4-{[(6- Chlorpyrid-3-yl)methyl](2,2-difluorethyl)amino}furan-2(5H)-on zu Salizylsäure von 1 : 1 erkannt werden kann. Eine Ubersicht über die wesentlichen Versuchs und Messdaten aus diesem Beispiel wird nachfolgenden Tabelle gegeben. The data were visualized after which a stoichiometric ratio of 4 - {[(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino} furan-2 (5H) -one to salicylic acid of 1: 1 was recognized can be. An overview of the essential test and measurement data from this example is given in the following table.
Parameter Wert  Parameter value
Temperatur (Messung) 100 K  Temperature (measurement) 100 K
Wellenlänge (Messung) 1,54178 Ä  Wavelength (measurement) 1.54178 Ä
Morphologie Monoklin  Morphology monoclinic
Raumgruppe P2(l)/n  Space group P2 (l) / n
Dimension der Einheitszelle a = 12,8275(3) Ä oc= 90°  Dimension of the unit cell a = 12.8275 (3) A oc = 90 °
b = 8,.3659(2) Ä ß= 96,537(3)° c = 35,0020(12) Ä γ = 90°  b = 8, .3659 (2) Ä ß = 96.537 (3) ° c = 35.0020 (12) Ä γ = 90 °
Volumen der Einheitszelle 3731,77(18) Ä3 Unit cell volume 3731.77 (18) A 3
Dichte (berechnet) 1,519 Mg/m3  Density (calculated) 1.519 Mg / m3
Absorptionskoeffizient 2,320 mm"1 Absorption coefficient 2.320 mm "1

Claims

Co-Kristall umfassend 4-{[(6-Chlo^yrid-3-yl)methyl](2,2-difluorethyl)arruno}furan-2(5H)-on, der dadurch gekennzeichnet ist, dass er als Co-Former Salizylsäure enthält. Co-crystal comprising 4 - {[(6-chloro-3-yl-3-yl) methyl] (2,2-difluoroethyl) -arrino} furan-2 (5H) -one, which is characterized in that it acts as a co-former Salicylic acid contains.
Co-Kristall gemäß Anspruch 1, dadurch gekennzeichnet, dass er aus 4-{[(6-Chlorpyrid-3- yl)methyl](2,2-difluorethyl)amino} furan-2(5H)-on und Salizylsäure besteht.  Co-crystal according to claim 1, characterized in that it consists of 4 - {[(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino} furan-2 (5H) -one and salicylic acid.
Co-Kristall gemäß Anspruch 2, dadurch gekennzeichnet, dass das stöchiometnsche Verhältnis von 4-{[(6-Chlo^yrid-3-yl)methyl](2,2-difluorethyl)amino}furan-2(5H)-on zu Salizylsäure 1 :1 beträgt.  Co-crystal according to claim 2, characterized in that the stoichiometric ratio of 4 - {[(6-chloro-3-yl) methyl] (2,2-difluoroethyl) amino} furan-2 (5H) -one to Salicylic acid is 1: 1.
Co-Kristall gemäß Anspruch 2 oder 3, dadurch gekennzeichnet, dass er monokline Morphologie aufweist.  Co-crystal according to claim 2 or 3, characterized in that it has monoclinic morphology.
Co-Kristall gemäß einem der Ansprüche 2 bis 4, dadurch gekennzeichnet, dass er die die Raumgruppe P2(l)/n aufweist.  Co-crystal according to one of claims 2 to 4, characterized in that it has the space group P2 (l) / n.
Co-Kristall gemäß einem der Ansprüche 2 bis 5, dadurch gekennzeichnet, dass er einen Schmelzpunkt im Bereich von 70°C bis 90°C besitzt.  Co-crystal according to one of claims 2 to 5, characterized in that it has a melting point in the range of 70 ° C to 90 ° C.
Verfahren zur Herstellung eines Co-Kristalls umfassend 4-{[(6-Chlorpyrid-3-yl)methyl](2,2- difluorethyl)amino}furan-2(5H)-on, dadurch gekennzeichnet, dass es mindestens die Schritte a) Vermengen von 4-{[(6-Chlo^yrid-3-yl)methyl](2,2-difluorethyl)arruno}furan-2(5H)-on mit Salizylsäure erhaltend eine Mischung A,  A process for producing a co-crystal comprising 4 - {[(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino} furan-2 (5H) -one, characterized in that it comprises at least steps a ) Mixing 4 - {[(6-chloro-3-yl) -methyl] (2,2-difluoroethyl) -arrino} furan-2 (5H) -one with salicylic acid to obtain a mixture A,
b) gegebenenfalls weiteres Vermengen der Mischung A mit einem Lösungsmittel erhaltend eine Mischung A' und b) optionally further mixing the mixture A with a solvent containing a mixture A 'and
c) Mahlen von Mischung A oder Mischung A' erhaltend den erfindungsgemäßen Co-Kristall umfasst. c) milling mixture A or mixture A 'containing the co-crystal according to the invention comprises.
Verfahren zur Herstellung eines Co-Kristalls umfassend 4-{[(6-Chlorpyrid-3-yl)methyl](2,2- difluorethyl)amino}furan-2(5H)-on, dadurch gekennzeichnet, dass es mindestens die Schritte a) Bereitstellen einer gesättigten Lösung (A) von 4-{[(6-Chlorpyrid-3-yl)methyl](2,2- difluorethyl)amino}furan-2(5H)-on und/oder einer gesättigten Lösung (B) von Salizylsäure, und  A process for producing a co-crystal comprising 4 - {[(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino} furan-2 (5H) -one, characterized in that it comprises at least steps a ) Providing a saturated solution (A) of 4 - {[(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) amino} furan-2 (5H) -one and / or a saturated solution (B) of salicylic acid, and
b) Vermengen von Lösungen (A) und (B) und/oder Hinzugeben von Salizylsäure als Feststo ff zu der Lösung (A) und/oder Hinzugeben von 4-{[(6-Chlorpyrid-3- yl)methyl](2,2-difluorethyl)amino}furan-2(5H)-on als Feststoff zu der Lösung (B) umfasst. b) mixing solutions (A) and (B) and / or adding salicylic acid as a solid to the solution (A) and / or adding 4 - {[(6-chloropyrid-3-yl) methyl] (2, 2-difluoroethyl) amino} furan-2 (5H) -one as a solid to the solution (B).
9. Verwendung von Co-Kristallen von 4-{[(6-Chlorpyrid-3-yl)methyl](2,2- difluorethyl)arrrino}furan-2(5H)-on mit Salizylsäure als Co-Former zur Bekämpfung von tierischen Schädlingen. 9. Use of co-crystals of 4 - {[(6-chloropyrid-3-yl) methyl] (2,2-difluoroethyl) arrrino} furan-2 (5H) -one with salicylic acid as a co-former to combat animal pests.
10. Verwendung gemäß Anspruch 9, dadurch gekennzeichnet, dass die tierischen Schädlinge Insekten, Spinnentieren und/oder Nematoden, die in der Landwirtschaft, in den Forsten, im Vorrats- und Materialschutz sowie auf dem Hygienesektor vorkommen, sind.  10. Use according to claim 9, characterized in that the animal pests insects, arachnids and / or nematodes, which occur in agriculture, in the forests, in the protection of stored products and on the hygiene sector.
11. Mittel zur Bekämpfung von tierischen Schädlingen, das Co-Kristalle wie in einem der Ansprüche 1 bis 6 definiert, enthält.  An animal pest controlling agent containing co-crystals as defined in any one of claims 1 to 6.
12. Mittel gemäß Anspruch 11, dadurch gekennzeichnet, dass die tierischen Schädlinge Insekten, Spinnentieren und/oder Nematoden, die in der Landwirtschaft, in den Forsten, im Vorrats- und Materialschutz sowie auf dem Hygienesektor vorkommen, sind.  12. Composition according to claim 11, characterized in that the animal pests are insects, arachnids and / or nematodes, which occur in agriculture, in the forestry, in the protection of stored products and on the hygiene sector.
13. Verfahren zum Schutz von Saatgut und/oder keimenden Pflanzen vor dem Befall von Schädlingen, in dem das Saatgut mit dem Mittel gemäß Anspruch 11 behandelt wird.  13. A method of protecting seed and / or germinating plants from attack by pests, in which the seed is treated with the agent according to claim 11.
14. Verfahren nach Anspruch 13, dadurch gekennzeichnet, dass das Saatgut transgenes Saatgut ist und dass die Schädlinge in der Landwirtschaft vorkommende Insekten, Spinnentiere und/oder Nematoden sind.  14. The method according to claim 13, characterized in that the seed is transgenic seed and that the pests are occurring in agriculture insects, arachnids and / or nematodes.
EP10773614A 2009-10-27 2010-10-26 Co-crystal of 4-{[(6-chloropyrid-3-yl)methyl](2,2-difluoroethyl)amino}­furan-2(5h)-one with salicylic acid and use thereof as pesticide Withdrawn EP2493884A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP10773614A EP2493884A1 (en) 2009-10-27 2010-10-26 Co-crystal of 4-{[(6-chloropyrid-3-yl)methyl](2,2-difluoroethyl)amino}­furan-2(5h)-one with salicylic acid and use thereof as pesticide

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09013510 2009-10-27
PCT/EP2010/066095 WO2011051242A1 (en) 2009-10-27 2010-10-26 Co-crystal of 4-{[(6-chloropyrid-3-yl)methyl](2,2-difluoroethyl)amino}­furan-2(5h)-one with salicylic acid and use thereof as pesticide
EP10773614A EP2493884A1 (en) 2009-10-27 2010-10-26 Co-crystal of 4-{[(6-chloropyrid-3-yl)methyl](2,2-difluoroethyl)amino}­furan-2(5h)-one with salicylic acid and use thereof as pesticide

Publications (1)

Publication Number Publication Date
EP2493884A1 true EP2493884A1 (en) 2012-09-05

Family

ID=41514978

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10773614A Withdrawn EP2493884A1 (en) 2009-10-27 2010-10-26 Co-crystal of 4-{[(6-chloropyrid-3-yl)methyl](2,2-difluoroethyl)amino}­furan-2(5h)-one with salicylic acid and use thereof as pesticide

Country Status (4)

Country Link
US (1) US20120252766A1 (en)
EP (1) EP2493884A1 (en)
CN (1) CN102686582A (en)
WO (1) WO2011051242A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014347949B2 (en) * 2013-11-13 2017-01-19 Nippon Soda Co., Ltd. Co-crystal and method for producing same
CN106561662A (en) * 2016-11-17 2017-04-19 佛山市盈辉作物科学有限公司 Disease-resistant insect-killing compound seed treating agent
CN109006470B (en) * 2018-07-23 2021-11-02 西南科技大学 Application of protective agent in60Method for cultivating new tulip variety by Co-gamma radiation mutagenesis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5436864B2 (en) 2006-02-27 2014-03-05 バーテックス ファーマシューティカルズ インコーポレイテッド Co-crystal containing VX-950 and pharmaceutical composition containing the same
DE102006015467A1 (en) * 2006-03-31 2007-10-04 Bayer Cropscience Ag New cyclic enamine ketone derivatives useful for controlling pests, especially insects
WO2008013823A2 (en) 2006-07-26 2008-01-31 Scios Inc. Co-crystals of (2r-trans)-6-chloro-5-[[4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-n,n,1-trimethyl-alpha-oxo-1h-indole-3-acetamide
TW200901889A (en) 2007-02-09 2009-01-16 Basf Se Crystalline complexes of agriculturally active organic compounds
EP2042496A1 (en) 2007-09-18 2009-04-01 Bayer CropScience AG Method for manufacturing 4-aminobut-2-enolids

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2011051242A1 *

Also Published As

Publication number Publication date
US20120252766A1 (en) 2012-10-04
WO2011051242A1 (en) 2011-05-05
CN102686582A (en) 2012-09-19

Similar Documents

Publication Publication Date Title
EP1677598B1 (en) Synergistic fungicidal active combinations
EP2955176B1 (en) Composition comprising crystalline form b of 1- (3-chloropyridin-2-yl)-n-[4-cyano-2-methyl-6-(methylcarbamoyl)phenyl]-3-([5-(trifluoromethyl)-2h- tetrazol-2-yl]methyl)-1h-pyrazol-5-carboxamide and its use
EP2220939B1 (en) Synergistic fungicidal combinations
DE60202132T2 (en) Fungicidal compositions based on pyridylmethylbenzamide derivatives and at least one Complex III inhibiting compound
DE2433067A1 (en) HERBICIDAL AGENTS
EP1463410B1 (en) Fungicide active substance combinations
DE10335183A1 (en) Fungicidal drug combinations
DE10228104A1 (en) Fungicidal active ingredient combination
EP1276375B1 (en) Fungicidal active ingredient combinations
WO2019197631A1 (en) Solid formulation of insecticidal mixtures
DE2433680B2 (en) 23-DUiydro-2 ^ -dimethyl-7-benzofuranyl-methyl-carbamate-N-aminosulfenyl derivatives, processes for their preparation and insecticidal preparations containing these compounds
DE2349745B2 (en) Plant growth regulating agents
DE102008006622A1 (en) Use of benzothiadiazoles
EP2475255A2 (en) Use of cyclic keto-enols for combating plant pathogenic bacteria
WO2011051242A1 (en) Co-crystal of 4-{[(6-chloropyrid-3-yl)methyl](2,2-difluoroethyl)amino}­furan-2(5h)-one with salicylic acid and use thereof as pesticide
DD145997A5 (en) MEDIUM FOR THE PROTECTION OF PLANT CULTURES
DE10349503A1 (en) Fungicidal drug combinations
EP3233810B1 (en) Novel crystal forms of the monosodium salt of foramsulfuron
EP2493883A1 (en) Co-crystal of 4-{[(6-chloropyrid-3-yl)methyl](2,2-difluoroethyl)amino}­furan-2(5h)-one with oxalic acid and use thereof as pesticide
EP2418954B1 (en) Imidacloprid containing co-crystal and method for producing same
EP2493882A1 (en) Co-crystal of 4-{[(6-chloropyrid-3-yl)methyl](2,2-difluoroethyl)­amino}­furan-2(5h)-one with benzoic acid and use thereof as a pesticide
DE10141617A1 (en) Fungicidal active ingredient combinations
DE2830700A1 (en) NEW 2-PYRIDON
DE69904955T2 (en) FUNGICIDAL COMPOSITIONS
DE102006046161A1 (en) New crystalline modified 4-((6-chloro-pyridin-3-ylmethyl)-methyl-amino)-5H-furan-2-one exhibiting reflex positions using copper potassium-alpha-radiation, useful e.g. to combat pest and harmful insects

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120529

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER INTELLECTUAL PROPERTY GMBH

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20140404

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140815